{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:26:48Z","timestamp":1791260808044,"version":"4.1.0"},"reference-count":295,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 2024 - ID. 30316"],"award-info":[{"award-number":["IG 2024 - ID. 30316"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR-MAD-2022-12375909"],"award-info":[{"award-number":["PNRR-MAD-2022-12375909"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00776-2","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:31:10Z","timestamp":1783006270000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting the cancer metabolism\u2014immunity interface: update and perspectives"],"prefix":"10.1186","volume":"15","author":[{"given":"Emma","family":"Di Carlo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"776_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","volume":"21","author":"ZE Stine","year":"2022","unstructured":"Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022;21:141\u201362. https:\/\/doi.org\/10.1038\/s41573-021-00339-6.","journal-title":"Nat Rev Drug Discov"},{"key":"776_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11306-016-1094-6","volume":"12","author":"RD Beger","year":"2016","unstructured":"Beger RD, Dunn W, Schmidt MA, Gross SS, Kirwan JA, et al. Metabolomics enables precision medicine: \u201ca white paper, community perspective.\u201d Metabolomics. 2016;12:149. https:\/\/doi.org\/10.1007\/s11306-016-1094-6.","journal-title":"Metabolomics"},{"key":"776_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/354671","volume":"2015","author":"A Zhang","year":"2015","unstructured":"Zhang A, Sun H, Yan G, Wang P, Wang X. Metabolomics for biomarker discovery: moving to the clinic. BioMed Res Int. 2015;2015:354671. https:\/\/doi.org\/10.1155\/2015\/354671.","journal-title":"BioMed Res Int"},{"key":"776_CR4","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.cell.2023.01.038","volume":"186","author":"LWS Finley","year":"2023","unstructured":"Finley LWS. What is cancer metabolism? Cell. 2023;186:1670\u201388. https:\/\/doi.org\/10.1016\/j.cell.2023.01.038.","journal-title":"Cell"},{"key":"776_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02119-3","volume":"23","author":"M Tufail","year":"2024","unstructured":"Tufail M, Jiang CH, Li N. Altered metabolism in cancer: insights into energy pathways and therapeutic targets. Mol Cancer. 2024;23:203. https:\/\/doi.org\/10.1186\/s12943-024-02119-3.","journal-title":"Mol Cancer"},{"key":"776_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.semcancer.2017.05.001","volume":"47","author":"AR Choudhury","year":"2017","unstructured":"Choudhury AR, Singh KK. Mitochondrial determinants of cancer health disparities. Semin Cancer Biol. 2017;47:125\u201346. https:\/\/doi.org\/10.1016\/j.semcancer.2017.05.001.","journal-title":"Semin Cancer Biol"},{"key":"776_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-023-00956-w","volume":"30","author":"SF Wang","year":"2023","unstructured":"Wang SF, Tseng LM, Lee HC. Role of mitochondrial alterations in human cancer progression and cancer immunity. J Biomed Sci. 2023;30:61. https:\/\/doi.org\/10.1186\/s12929-023-00956-w.","journal-title":"J Biomed Sci"},{"issue":"Suppl 1","key":"776_CR8","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.arr.2010.08.009","volume":"9","author":"HC Lee","year":"2010","unstructured":"Lee HC, Chang CM, Chi CW. Somatic mutations of mitochondrial DNA in aging and cancer progression. Ageing Res Rev. 2010;9(Suppl 1):S47-58. https:\/\/doi.org\/10.1016\/j.arr.2010.08.009.","journal-title":"Ageing Res Rev"},{"key":"776_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.canlet.2014.02.023","volume":"356","author":"E Desideri","year":"2015","unstructured":"Desideri E, Vegliante R, Ciriolo MR. Mitochondrial dysfunctions in cancer: genetic defects and oncogenic signaling impinging on TCA cycle activity. Cancer Lett. 2015;356:217\u201323. https:\/\/doi.org\/10.1016\/j.canlet.2014.02.023.","journal-title":"Cancer Lett"},{"key":"776_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.molmed.2011.06.001","volume":"17","author":"N Raimundo","year":"2011","unstructured":"Raimundo N, Baysal BE, Shadel GS. Revisiting the TCA cycle: signaling to tumor formation. Trends Mol Med. 2011;17:641\u20139. https:\/\/doi.org\/10.1016\/j.molmed.2011.06.001.","journal-title":"Trends Mol Med"},{"key":"776_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrc3038","volume":"11","author":"WH Koppenol","year":"2011","unstructured":"Koppenol WH, Bounds PL, Dang CV. Otto Warburg\u2019s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11:325\u201337. https:\/\/doi.org\/10.1038\/nrc3038.","journal-title":"Nat Rev Cancer"},{"key":"776_CR12","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41586-025-08588-w","volume":"640","author":"G Guzelsoy","year":"2025","unstructured":"Guzelsoy G, Elorza SD, Ros M, Schachtner LT, Hayashi M, Hobson-Gutierrez S, et al. Cooperative nutrient scavenging is an evolutionary advantage in cancer. Nature. 2025;640:534\u201342. https:\/\/doi.org\/10.1038\/s41586-025-08588-w.","journal-title":"Nature"},{"key":"776_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.trecan.2017.01.005","volume":"3","author":"AA Cluntun","year":"2017","unstructured":"Cluntun AA, Lukey MJ, Cerione RA, Locasale JW. Glutamine metabolism in cancer: understanding the heterogeneity. Trends Cancer. 2017;3:169\u201380. https:\/\/doi.org\/10.1016\/j.trecan.2017.01.005.","journal-title":"Trends Cancer"},{"key":"776_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-02018-6","volume":"23","author":"D Nan","year":"2025","unstructured":"Nan D, Yao W, Huang L, Liu R, Chen X, Xia W, et al. Glutamine and cancer: metabolism, immune microenvironment, and therapeutic targets. Cell Commun Signal. 2025;23:45. https:\/\/doi.org\/10.1186\/s12964-024-02018-6.","journal-title":"Cell Commun Signal"},{"key":"776_CR15","doi-asserted-by":"publisher","unstructured":"De Santis MC, Porporato PE, Martini M, Morandi A. Signaling pathways regulating redox balance in cancer metabolism. Front Oncol. 2018;8. https:\/\/doi.org\/10.3389\/fonc.2018.00126.","DOI":"10.3389\/fonc.2018.00126"},{"key":"776_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13091109","volume":"13","author":"E Di Carlo","year":"2024","unstructured":"Di Carlo E, Sorrentino C. Oxidative stress and age-related tumors. Antioxidants Basel. 2024;13:1109. https:\/\/doi.org\/10.3390\/antiox13091109.","journal-title":"Antioxidants Basel"},{"key":"776_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/cr.2017.155","volume":"28","author":"PE Porporato","year":"2018","unstructured":"Porporato PE, Filigheddu N, Pedro JMBS, Kroemer G, Galluzzi L. Mitochondrial metabolism and cancer. Cell Res. 2018;28:265\u201380. https:\/\/doi.org\/10.1038\/cr.2017.155.","journal-title":"Cell Res"},{"key":"776_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188534","volume":"1876","author":"YQ Tan","year":"2021","unstructured":"Tan YQ, Zhang X, Zhang S, Zhu T, Garg M, Lobie PE, et al. Mitochondria: the metabolic switch of cellular oncogenic transformation. Biochimica et Biophysica Acta (BBA) Rev Cancer. 2021;1876:188534. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188534.","journal-title":"Biochimica et Biophysica Acta (BBA) Rev Cancer"},{"key":"776_CR19","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.cmet.2014.03.003","volume":"19","author":"H Xie","year":"2014","unstructured":"Xie H, Hanai J, Ren JG, Kats L, Burgess K, Bhargava P, et al. Targeting lactate dehydrogenase\u2014a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metab. 2014;19:795\u2013809. https:\/\/doi.org\/10.1016\/j.cmet.2014.03.003.","journal-title":"Cell Metab"},{"issue":"2","key":"776_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.devcel.2020.06.018","volume":"54","author":"F Li","year":"2020","unstructured":"Li F, Simon MC. Cancer cells don\u2019t live alone: metabolic communication within tumor microenvironments. Dev Cell. 2020;54(2):183\u201395. https:\/\/doi.org\/10.1016\/j.devcel.2020.06.018.","journal-title":"Dev Cell"},{"key":"776_CR21","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/cas.15722","volume":"114","author":"R Nakahara","year":"2023","unstructured":"Nakahara R, Maeda K, Aki S, Osawa T. Metabolic adaptations of cancer in extreme tumor microenvironments. Cancer Sci. 2023;114:1200\u20137. https:\/\/doi.org\/10.1111\/cas.15722.","journal-title":"Cancer Sci"},{"key":"776_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00689-6","volume":"14","author":"R Wang","year":"2025","unstructured":"Wang R, Zhuang J, Zhang Q, Wu W, Yu X, Zhang H, et al. Decoding the metabolic dialogue in the tumor microenvironment: from immune suppression to precision cancer therapies. Exp Hematol Oncol. 2025;14:99. https:\/\/doi.org\/10.1186\/s40164-025-00689-6.","journal-title":"Exp Hematol Oncol"},{"issue":"26","key":"776_CR23","doi-asserted-by":"publisher","first-page":"00037","DOI":"10.1016\/j.tcb.2026.03.006","volume":"S0962\u20138924","author":"YL Cao","year":"2026","unstructured":"Cao YL, Yang CP, Shen B, Hu J, Gao S. Targeting mitochondrial dynamics against cancer. Trends Cell Biol. 2026;S0962\u20138924(26):00037\u201341. https:\/\/doi.org\/10.1016\/j.tcb.2026.03.006.","journal-title":"Trends Cell Biol"},{"key":"776_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00482-x","volume":"13","author":"J Yang","year":"2024","unstructured":"Yang J, Shay C, Saba NF, Teng Y. Cancer metabolism and carcinogenesis. Exp Hematol Oncol. 2024;13:10. https:\/\/doi.org\/10.1186\/s40164-024-00482-x.","journal-title":"Exp Hematol Oncol"},{"key":"776_CR25","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.chembiol.2024.02.001","volume":"31","author":"NM Chapman","year":"2024","unstructured":"Chapman NM, Chi H. Metabolic rewiring and communication in cancer immunity. Cell Chem Biol. 2024;31:862\u201383. https:\/\/doi.org\/10.1016\/j.chembiol.2024.02.001.","journal-title":"Cell Chem Biol"},{"issue":"9","key":"776_CR26","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41577-024-01026-4","volume":"24","author":"M De Martino","year":"2024","unstructured":"De Martino M, Rathmell JC, Galluzzi L, Vanpouille-Box C. Cancer cell metabolism and antitumour immunity. Nat Rev Immunol. 2024;24(9):654\u201369. https:\/\/doi.org\/10.1038\/s41577-024-01026-4.","journal-title":"Nat Rev Immunol"},{"key":"776_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.115206","volume":"44","author":"JE Ricci","year":"2025","unstructured":"Ricci JE. Tumor-induced metabolic immunosuppression: mechanisms and therapeutic targets. Cell Rep. 2025;44:115206. https:\/\/doi.org\/10.1016\/j.celrep.2024.115206.","journal-title":"Cell Rep"},{"key":"776_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00719-3","volume":"14","author":"X Ji","year":"2025","unstructured":"Ji X, Xia L. Lactate and lactylation in cancer: drivers of immune suppression and microenvironmental reprogramming. Exp Hematol Oncol. 2025;14:128. https:\/\/doi.org\/10.1186\/s40164-025-00719-3.","journal-title":"Exp Hematol Oncol"},{"key":"776_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1563303","volume":"16","author":"XY Gu","year":"2025","unstructured":"Gu XY, Yang JL, Lai R, Zhou ZJ, Tang D, Hu L, et al. Impact of lactate on immune cell function in the tumor microenvironment: mechanisms and therapeutic perspectives. Front Immunol. 2025;16:1563303. https:\/\/doi.org\/10.3389\/fimmu.2025.1563303.","journal-title":"Front Immunol"},{"key":"776_CR30","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.cmet.2016.12.018","volume":"25","author":"A Angelin","year":"2017","unstructured":"Angelin A, Gil-de-G\u00f3mez L, Dahiya S, Jiao J, Guo L, Levine MH, et al. Foxp3 reprograms T Cell metabolism to function in low-glucose, high-lactate environments. Cell Metab. 2017;25:1282-1293.e7. https:\/\/doi.org\/10.1016\/j.cmet.2016.12.018.","journal-title":"Cell Metab"},{"key":"776_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1013686","volume":"13","author":"HC Zhou","year":"2022","unstructured":"Zhou HC, Yu WW, Yan XY, Liang XQ, Ma XF, Long JP, et al. Lactate-driven macrophage polarization in the inflammatory microenvironment alleviates intestinal inflammation. Front Immunol. 2022;13:1013686. https:\/\/doi.org\/10.3389\/fimmu.2022.1013686.","journal-title":"Front Immunol"},{"key":"776_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1208870","volume":"14","author":"H Tao","year":"2023","unstructured":"Tao H, Zhong X, Zeng A, Song L. Unveiling the veil of lactate in tumor-associated macrophages: a successful strategy for immunometabolic therapy. Front Immunol. 2023;14:1208870. https:\/\/doi.org\/10.3389\/fimmu.2023.1208870.","journal-title":"Front Immunol"},{"key":"776_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15620","volume":"8","author":"SJ Lawless","year":"2017","unstructured":"Lawless SJ, Kedia-Mehta N, Walls JF, McGarrigle R, Convery O, Sinclair LV, et al. Glucose represses dendritic cell-induced T cell responses. Nat Commun. 2017;8:15620. https:\/\/doi.org\/10.1038\/ncomms15620.","journal-title":"Nat Commun"},{"key":"776_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.05.017","volume":"30","author":"PM Thwe","year":"2019","unstructured":"Thwe PM, Pelgrom LR, Cooper R, Beauchamp S, Reisz JA, D\u2019Alessandro A, et al. Cell-intrinsic glycogen metabolism supports early glycolytic reprogramming required for dendritic cell immune responses. Cell Metab. 2019;30:225. https:\/\/doi.org\/10.1016\/j.cmet.2019.05.017.","journal-title":"Cell Metab"},{"key":"776_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03192-8","volume":"43","author":"B Zhang","year":"2024","unstructured":"Zhang B, Ohuchida K, Tsutsumi C, Shimada Y, Mochida Y, Oyama K, et al. Dynamic glycolytic reprogramming effects on dendritic cells in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res. 2024;43:271. https:\/\/doi.org\/10.1186\/s13046-024-03192-8.","journal-title":"J Exp Clin Cancer Res"},{"key":"776_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.688485","volume":"12","author":"HL Caslin","year":"2021","unstructured":"Caslin HL, Abebayehu D, Pinette JA, Ryan JJ. Lactate is a metabolic mediator that shapes immune cell fate and function. Front Physiol. 2021;12:688485. https:\/\/doi.org\/10.3389\/fphys.2021.688485.","journal-title":"Front Physiol"},{"key":"776_CR37","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.tips.2023.04.006","volume":"44","author":"TW Stone","year":"2023","unstructured":"Stone TW, Williams RO. Modulation of T cells by tryptophan metabolites in the kynurenine pathway. Trends Pharmacol Sci. 2023;44:442\u201356. https:\/\/doi.org\/10.1016\/j.tips.2023.04.006.","journal-title":"Trends Pharmacol Sci"},{"key":"776_CR38","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202256156","volume":"24","author":"A Pelletier","year":"2023","unstructured":"Pelletier A, Nelius E, Fan Z, Khatchatourova E, Alvarado-Diaz A, He J, et al. Resting natural killer cell homeostasis relies on tryptophan\/NAD+ metabolism and HIF-1\u03b1. EMBO Rep. 2023;24:e56156. https:\/\/doi.org\/10.15252\/embr.202256156.","journal-title":"EMBO Rep"},{"key":"776_CR39","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cellimm.2012.11.018","volume":"280","author":"B Lamas","year":"2012","unstructured":"Lamas B, Vergnaud-Gauduchon J, Goncalves-Mendes N, Perche O, Rossary A, Vasson MP, et al. Altered functions of natural killer cells in response to L-Arginine availability. Cell Immunol. 2012;280:182\u201390. https:\/\/doi.org\/10.1016\/j.cellimm.2012.11.018.","journal-title":"Cell Immunol"},{"key":"776_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/imr.13316","volume":"323","author":"A Moinuddin","year":"2024","unstructured":"Moinuddin A, Poznanski SM, Portillo AL, Monteiro JK, Ashkar AA. Metabolic adaptations determine whether natural killer cells fail or thrive within the tumor microenvironment. Immunol Rev. 2024;323:19\u201339. https:\/\/doi.org\/10.1111\/imr.13316.","journal-title":"Immunol Rev"},{"key":"776_CR41","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s12276-023-01028-7","volume":"55","author":"SK Seo","year":"2023","unstructured":"Seo SK, Kwon B. Immune regulation through tryptophan metabolism. Exp Mol Med. 2023;55:1371\u20139. https:\/\/doi.org\/10.1038\/s12276-023-01028-7.","journal-title":"Exp Mol Med"},{"key":"776_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.regen.2019.100015","volume":"5","author":"E Bracho-Sanchez","year":"2019","unstructured":"Bracho-Sanchez E, Hassanzadeh A, Brusko MA, Wallet MA, Keselowsky BG. Dendritic cells treated with exogenous indoleamine 2,3-dioxygenase maintain an immature phenotype and suppress antigen-specific T cell proliferation. J Immunol Regen Med. 2019;5:100015. https:\/\/doi.org\/10.1016\/j.regen.2019.100015.","journal-title":"J Immunol Regen Med"},{"key":"776_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102096","volume":"49","author":"C Chen","year":"2024","unstructured":"Chen C, Xie Y, Qian S. Multifaceted role of GCN2 in tumor adaptation and therapeutic targeting. Transl Oncol. 2024;49:102096. https:\/\/doi.org\/10.1016\/j.tranon.2024.102096.","journal-title":"Transl Oncol"},{"key":"776_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01200-4","volume":"14","author":"W Yu","year":"2021","unstructured":"Yu W, Lei Q, Yang L, Qin G, Liu S, Wang D, et al. Contradictory roles of lipid metabolism in immune response within the tumor microenvironment. J Hematol Oncol. 2021;14:187. https:\/\/doi.org\/10.1186\/s13045-021-01200-4.","journal-title":"J Hematol Oncol"},{"key":"776_CR45","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/s41423-024-01224-z","volume":"21","author":"Y Tang","year":"2024","unstructured":"Tang Y, Chen Z, Zuo Q, Kang Y. Regulation of CD8+ T cells by lipid metabolism in cancer progression. Cell Mol Immunol. 2024;21:1215\u201330. https:\/\/doi.org\/10.1038\/s41423-024-01224-z.","journal-title":"Cell Mol Immunol"},{"key":"776_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101831","volume":"5","author":"JP Gu\u00e9gan","year":"2024","unstructured":"Gu\u00e9gan JP, Peyraud F, Dadone-Montaudie B, Teyssonneau D, Palmieri LJ, Clot E, et al. Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response. Cell Rep Med. 2024;5:101831. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101831.","journal-title":"Cell Rep Med"},{"key":"776_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-025-00267-6","volume":"6","author":"Z Yan","year":"2025","unstructured":"Yan Z, Wang C, Wu J, Wang J, Ma T. TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives. Mol Biomed. 2025;6:27. https:\/\/doi.org\/10.1186\/s43556-025-00267-6.","journal-title":"Mol Biomed"},{"key":"776_CR48","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41586-021-03235-6","volume":"591","author":"SA Lim","year":"2021","unstructured":"Lim SA, Wei J, Nguyen TM, Shi H, Su W, Palacios G, et al. Lipid signalling enforces functional specialization of Treg cells in tumours. Nature. 2021;591:306\u201311. https:\/\/doi.org\/10.1038\/s41586-021-03235-6.","journal-title":"Nature"},{"key":"776_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00588-8","volume":"12","author":"Y Shan","year":"2024","unstructured":"Shan Y, Xie T, Sun Y, Lu Z, Topatana W, Juengpanich S, et al. Lipid metabolism in tumor-infiltrating regulatory T cells: perspective to precision immunotherapy. Biomark Res. 2024;12:41. https:\/\/doi.org\/10.1186\/s40364-024-00588-8.","journal-title":"Biomark Res"},{"key":"776_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01498-2","volume":"16","author":"HR Jin","year":"2023","unstructured":"Jin HR, Wang J, Wang ZJ, Xi MJ, Xia BH, Deng K, et al. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. J Hematol Oncol. 2023;16:103. https:\/\/doi.org\/10.1186\/s13045-023-01498-2.","journal-title":"J Hematol Oncol"},{"key":"776_CR51","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1038\/s41388-025-03458-1","volume":"44","author":"J Saravia","year":"2025","unstructured":"Saravia J, Chi H. Immunometabolism of regulatory T cells in cancer. Oncogene. 2025;44:2011\u201324. https:\/\/doi.org\/10.1038\/s41388-025-03458-1.","journal-title":"Oncogene"},{"key":"776_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1435480","volume":"14","author":"G Pascual","year":"2024","unstructured":"Pascual G, Benitah SA. Lipids in the tumor microenvironment: immune modulation and metastasis. Front Oncol. 2024;14:1435480. https:\/\/doi.org\/10.3389\/fonc.2024.1435480.","journal-title":"Front Oncol"},{"key":"776_CR53","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1111\/cas.14616","volume":"111","author":"Q Luo","year":"2020","unstructured":"Luo Q, Zheng N, Jiang L, Wang T, Zhang P, Liu Y, et al. Lipid accumulation in macrophages confers protumorigenic polarization and immunity in gastric cancer. Cancer Sci. 2020;111:4000\u201311. https:\/\/doi.org\/10.1111\/cas.14616.","journal-title":"Cancer Sci"},{"key":"776_CR54","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/imr.13215","volume":"317","author":"Z You","year":"2023","unstructured":"You Z, Chi H. Lipid metabolism in dendritic cell biology. Immunol Rev. 2023;317:137\u201351. https:\/\/doi.org\/10.1111\/imr.13215.","journal-title":"Immunol Rev"},{"key":"776_CR55","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/nri.2017.103","volume":"17","author":"CT Taylor","year":"2017","unstructured":"Taylor CT, Colgan SP. Regulation of immunity and inflammation by hypoxia in immunological niches. Nat Rev Immunol. 2017;17:774\u201385. https:\/\/doi.org\/10.1038\/nri.2017.103.","journal-title":"Nat Rev Immunol"},{"key":"776_CR56","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.immuni.2025.02.008","volume":"58","author":"A Llibre","year":"2025","unstructured":"Llibre A, Kucuk S, Gope A, Certo M, Mauro C. Lactate: a key regulator of the immune response. Immunity. 2025;58:535\u201354. https:\/\/doi.org\/10.1016\/j.immuni.2025.02.008.","journal-title":"Immunity"},{"key":"776_CR57","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.bbabio.2016.03.012","volume":"1857","author":"L Tretter","year":"2016","unstructured":"Tretter L, Patocs A, Chinopoulos C. Succinate, an intermediate in metabolism, signal transduction, ROS, hypoxia, and tumorigenesis. Biochim Biophys Acta. 2016;1857:1086\u2013101. https:\/\/doi.org\/10.1016\/j.bbabio.2016.03.012.","journal-title":"Biochim Biophys Acta"},{"key":"776_CR58","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1134\/S0006297920120160","volume":"85","author":"AY Andreyev","year":"2020","unstructured":"Andreyev AY, Kushnareva YE, Starkova NN, Starkov AA. Metabolic ROS signaling: to immunity and beyond. Biochemistry (Mosc). 2020;85:1650\u201367. https:\/\/doi.org\/10.1134\/S0006297920120160.","journal-title":"Biochemistry (Mosc)"},{"key":"776_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e24454","volume":"10","author":"M Cai","year":"2024","unstructured":"Cai M, Zhao J, Ding Q, Wei J. Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity. Heliyon. 2024;10:e24454. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24454.","journal-title":"Heliyon"},{"key":"776_CR60","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1126\/science.abj5104","volume":"377","author":"G Notarangelo","year":"2022","unstructured":"Notarangelo G, Spinelli JB, Perez EM, Baker GJ, Kurmi K, Elia I, et al. Oncometabolite d-2HG alters T cell metabolism to impair CD8+ T cell function. Science. 2022;377:1519\u201329. https:\/\/doi.org\/10.1126\/science.abj5104.","journal-title":"Science"},{"key":"776_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115432","volume":"44","author":"EJ Kay","year":"2025","unstructured":"Kay EJ, Zanivan S. The tumor microenvironment is an ecosystem sustained by metabolic interactions. Cell Rep. 2025;44:115432. https:\/\/doi.org\/10.1016\/j.celrep.2025.115432.","journal-title":"Cell Rep"},{"key":"776_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105966","volume":"174","author":"Y Chen","year":"2021","unstructured":"Chen Y, Liu B, Wei Y, Kuang DM. Influence of gut and intratumoral microbiota on the immune microenvironment and anti-cancer therapy. Pharmacol Res. 2021;174:105966. https:\/\/doi.org\/10.1016\/j.phrs.2021.105966.","journal-title":"Pharmacol Res"},{"key":"776_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2023.127392","volume":"272","author":"Y Liu","year":"2023","unstructured":"Liu Y, Pei Z, Pan T, Wang H, Chen W, Lu W. Indole metabolites and colorectal cancer: gut microbial tryptophan metabolism, host gut microbiome biomarkers, and potential intervention mechanisms. Microbiol Res. 2023;272:127392. https:\/\/doi.org\/10.1016\/j.micres.2023.127392.","journal-title":"Microbiol Res"},{"key":"776_CR64","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.tips.2020.11.006","volume":"42","author":"M Modoux","year":"2021","unstructured":"Modoux M, Rolhion N, Mani S, Sokol H. Tryptophan metabolism as a pharmacological target. Trends Pharmacol Sci. 2021;42:60\u201373. https:\/\/doi.org\/10.1016\/j.tips.2020.11.006.","journal-title":"Trends Pharmacol Sci"},{"key":"776_CR65","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.molcel.2012.08.033","volume":"48","author":"DR Donohoe","year":"2012","unstructured":"Donohoe DR, Collins LB, Wali A, Bigler R, Sun W, Bultman SJ. The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol Cell. 2012;48:612\u201326. https:\/\/doi.org\/10.1016\/j.molcel.2012.08.033.","journal-title":"Mol Cell"},{"key":"776_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1638352","volume":"16","author":"Y Tong","year":"2025","unstructured":"Tong Y, Lou X. Interplay between bile acids, gut microbiota, and the tumor immune microenvironment: mechanistic insights and therapeutic strategies. Front Immunol. 2025;16:1638352. https:\/\/doi.org\/10.3389\/fimmu.2025.1638352.","journal-title":"Front Immunol"},{"key":"776_CR67","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2025.5730","volume":"66","author":"Z Li","year":"2025","unstructured":"Li Z, Deng L, Cheng M, Ye X, Yang N, Fan Z, et al. Emerging role of bile acids in colorectal liver metastasis: from molecular mechanism to clinical significance (Review). Int J Oncol. 2025;66:24. https:\/\/doi.org\/10.3892\/ijo.2025.5730.","journal-title":"Int J Oncol"},{"key":"776_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2023.100740","volume":"31","author":"Z Li","year":"2023","unstructured":"Li Z, Cui J. Targeting the lactic acid metabolic pathway for antitumor therapy. Mol Ther Oncolytics. 2023;31:100740. https:\/\/doi.org\/10.1016\/j.omto.2023.100740.","journal-title":"Mol Ther Oncolytics"},{"key":"776_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-022-00878-z","volume":"29","author":"CC Kuo","year":"2022","unstructured":"Kuo CC, Wu JY, Wu KK. Cancer-derived extracellular succinate: a driver of cancer metastasis. J Biomed Sci. 2022;29:93. https:\/\/doi.org\/10.1186\/s12929-022-00878-z.","journal-title":"J Biomed Sci"},{"key":"776_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-76109-y","volume":"10","author":"N Jacob","year":"2020","unstructured":"Jacob N, Jaiswal S, Maheshwari D, et al. Butyrate induced Tregs are capable of migration from the GALT to the pancreas to restore immunological tolerance during type-1 diabetes. Sci Rep. 2020;10:19120. https:\/\/doi.org\/10.1038\/s41598-020-76109-y.","journal-title":"Sci Rep"},{"key":"776_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202411086","volume":"12","author":"B Chen","year":"2025","unstructured":"Chen B, Guan L, Wu C, Gong Y, Wu L, Zhang M, et al. Gut microbiota-butyrate-PPAR\u03b3 axis modulates adipose regulatory T cell population. Adv Sci. 2025;12:e2411086. https:\/\/doi.org\/10.1002\/advs.202411086.","journal-title":"Adv Sci"},{"key":"776_CR72","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2377567","volume":"16","author":"S Zhao","year":"2024","unstructured":"Zhao S, Zhang H, Zhu H, Zhao T, Tu J, Yin X, et al. Gut microbiota promotes macrophage M1 polarization in hepatic sinusoidal obstruction syndrome via regulating intestinal barrier function mediated by butyrate. Gut Microbes. 2024;16:2377567. https:\/\/doi.org\/10.1080\/19490976.2024.2377567.","journal-title":"Gut Microbes"},{"key":"776_CR73","doi-asserted-by":"publisher","unstructured":"Jiang Q, Qiu Y, Kurland IJ, Drlica K, Subbian S, Tyagi S, et al. Glutamine is required for M1-like polarization of macrophages in response to mycobacterium tuberculosis infection. mBio. 2022;13:e0127422. https:\/\/doi.org\/10.1128\/mbio.01274-22.","DOI":"10.1128\/mbio.01274-22"},{"key":"776_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen S, Saeed AFUH, Liu Q, Jiang Q, Xu H, Xiao GG, et al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8:207. https:\/\/doi.org\/10.1038\/s41392-023-01452-1.","journal-title":"Signal Transduct Target Ther"},{"key":"776_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/srep24838","volume":"6","author":"J Ji","year":"2016","unstructured":"Ji J, Shu D, Zheng M, Wang J, Luo C, Wang Y, et al. Microbial metabolite butyrate facilitates M2 macrophage polarization and function. Sci Rep. 2016;6:24838. https:\/\/doi.org\/10.1038\/srep24838.","journal-title":"Sci Rep"},{"key":"776_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e35755","volume":"10","author":"H Lun","year":"2024","unstructured":"Lun H, Li P, Li J, Liu F. The effect of intestinal flora metabolites on macrophage polarization. Heliyon. 2024;10:e35755. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e35755.","journal-title":"Heliyon"},{"key":"776_CR77","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41435-025-00338-2","volume":"26","author":"F Carlini","year":"2025","unstructured":"Carlini F, Squillario M, Casella V, Capaia M, Lusi V, Bagnara D, et al. Butyrate enhances CD56bright NK cell-driven killing of activated T cells and modulates NK cell chromatin accessibility. Genes Immun. 2025;26:342\u201351. https:\/\/doi.org\/10.1038\/s41435-025-00338-2.","journal-title":"Genes Immun"},{"key":"776_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-29731-5","volume":"13","author":"V Zaiatz-Bittencourt","year":"2023","unstructured":"Zaiatz-Bittencourt V, Jones F, Tosetto M, Scaife C, Cagney G, Jones E, et al. Butyrate limits human natural killer cell effector function. Sci Rep. 2023;13:2715. https:\/\/doi.org\/10.1038\/s41598-023-29731-5.","journal-title":"Sci Rep"},{"key":"776_CR79","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41385-020-0312-8","volume":"14","author":"A Sepahi","year":"2021","unstructured":"Sepahi A, Liu Q, Friesen L, Kim CH. Dietary fiber metabolites regulate innate lymphoid cell responses. Mucosal Immunol. 2021;14:317\u201330. https:\/\/doi.org\/10.1038\/s41385-020-0312-8.","journal-title":"Mucosal Immunol"},{"key":"776_CR80","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00109-025-02530-3","volume":"103","author":"H Tao","year":"2025","unstructured":"Tao H, Geng J, Bai L, Su D, Zhao Y, Xu G, et al. Regulation of innate lymphoid cell by microbial metabolites. J Mol Med (Berl). 2025;103:491\u2013509. https:\/\/doi.org\/10.1007\/s00109-025-02530-3.","journal-title":"J Mol Med (Berl)"},{"key":"776_CR81","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","volume":"28","author":"L Derosa","year":"2022","unstructured":"Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med. 2022;28:315\u201324. https:\/\/doi.org\/10.1038\/s41591-021-01655-5.","journal-title":"Nat Med"},{"key":"776_CR82","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91\u20137. https:\/\/doi.org\/10.1126\/science.aan3706.","journal-title":"Science"},{"key":"776_CR83","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","volume":"28","author":"N Chaput","year":"2017","unstructured":"Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28:1368\u201379. https:\/\/doi.org\/10.1093\/annonc\/mdx108.","journal-title":"Ann Oncol"},{"key":"776_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-89406-1","volume":"15","author":"A Grenda","year":"2025","unstructured":"Grenda A, Iwan E, Ku\u017anar-Kami\u0144ska B, Bomba A, Bieli\u0144ska K, Krawczyk P, et al. Gut microbial predictors of first-line immunotherapy efficacy in advanced NSCLC patients. Sci Rep. 2025;15:6139. https:\/\/doi.org\/10.1038\/s41598-025-89406-1.","journal-title":"Sci Rep"},{"key":"776_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.seminoncol.2025.152398","volume":"52","author":"MJ Saadh","year":"2025","unstructured":"Saadh MJ, Allela OQB, Ballal S, Mahdi MS, Chahar M, Verma R, et al. The effects of microbiota-derived short-chain fatty acids on T lymphocytes: from autoimmune diseases to cancer. Semin Oncol. 2025;52:152398. https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152398.","journal-title":"Semin Oncol"},{"key":"776_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01946-6","volume":"9","author":"Z Ma","year":"2024","unstructured":"Ma Z, Zuo T, Frey N, Rangrez AY. A systematic framework for understanding the microbiome in human health and disease: from basic principles to clinical translation. Signal Transduct Target Ther. 2024;9:237. https:\/\/doi.org\/10.1038\/s41392-024-01946-6.","journal-title":"Signal Transduct Target Ther"},{"key":"776_CR87","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1038\/s41388-020-1341-1","volume":"39","author":"W Fong","year":"2020","unstructured":"Fong W, Li Q, Yu J. Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer. Oncogene. 2020;39:4925\u201343. https:\/\/doi.org\/10.1038\/s41388-020-1341-1.","journal-title":"Oncogene"},{"key":"776_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115332","volume":"210","author":"YS Cho","year":"2024","unstructured":"Cho YS, Han K, Xu J, Moon JJ. Novel strategies for modulating the gut microbiome for cancer therapy. Adv Drug Deliv Rev. 2024;210:115332. https:\/\/doi.org\/10.1016\/j.addr.2024.115332.","journal-title":"Adv Drug Deliv Rev"},{"key":"776_CR89","doi-asserted-by":"publisher","first-page":"208","DOI":"10.4049\/jimmunol.2300480","volume":"212","author":"K Han","year":"2024","unstructured":"Han K, Xu J, Xie F, Crowther J, Moon JJ. Engineering strategies to modulate the gut microbiome and immune system. J Immunol. 2024;212:208\u201315. https:\/\/doi.org\/10.4049\/jimmunol.2300480.","journal-title":"J Immunol"},{"key":"776_CR90","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.molmed.2023.08.004","volume":"29","author":"N Guillot","year":"2023","unstructured":"Guillot N, Rom\u00e9o B, Manesh SS, Milano G, Brest P, Zitvogel L, et al. Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality. Trends Mol Med. 2023;29:897\u2013911. https:\/\/doi.org\/10.1016\/j.molmed.2023.08.004.","journal-title":"Trends Mol Med"},{"key":"776_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0592-6","volume":"11","author":"M Yi","year":"2018","unstructured":"Yi M, Yu S, Qin S, Liu Q, Xu H, Zhao W, et al. Gut microbiome modulates efficacy of immune checkpoint inhibitors. J Hematol Oncol. 2018;11:47. https:\/\/doi.org\/10.1186\/s13045-018-0592-6.","journal-title":"J Hematol Oncol"},{"key":"776_CR92","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41573-025-01227-z","volume":"24","author":"MP Trefny","year":"2025","unstructured":"Trefny MP, Kroemer G, Zitvogel L, Kobold S. Metabolites as agents and targets for cancer immunotherapy. Nat Rev Drug Discov. 2025;24:764\u201384. https:\/\/doi.org\/10.1038\/s41573-025-01227-z.","journal-title":"Nat Rev Drug Discov"},{"key":"776_CR93","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010681","volume":"13","author":"MK Wong","year":"2025","unstructured":"Wong MK, Boukhaled GM, Armstrong E, Liu R, Heirali AA, Yee NR, et al. Microbial ecosystem therapeutics 4 (MET4) elicits treatment-specific IgG responses associated with changes in gut microbiota in immune checkpoint inhibitor recipients with advanced solid tumors. J Immunother Cancer. 2025;13:e010681. https:\/\/doi.org\/10.1136\/jitc-2024-010681.","journal-title":"J Immunother Cancer"},{"key":"776_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2023.101828","volume":"62-63","author":"E Rinninella","year":"2023","unstructured":"Rinninella E, Tohumcu E, Raoul P, Fiorani M, Cintoni M, Mele MC, et al. The role of diet in shaping human gut microbiota. Best Pract Res Clin Gastroenterol. 2023;62\u201363:101828. https:\/\/doi.org\/10.1016\/j.bpg.2023.101828.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"776_CR95","doi-asserted-by":"publisher","first-page":"163","DOI":"10.20892\/j.issn.2095-3941.2021.0461","volume":"19","author":"L Qian","year":"2022","unstructured":"Qian L, Zhang F, Yin M, Lei Q. Cancer metabolism and dietary interventions. Cancer Biol Med. 2022;19:163\u201374. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2021.0461.","journal-title":"Cancer Biol Med"},{"key":"776_CR96","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041549","volume":"14","author":"JW Locasale","year":"2024","unstructured":"Locasale JW, Goncalves MD, Di Tano M, Burgos-Barragan G. Diet and cancer metabolism. Cold Spring Harb Perspect Med. 2024;14:a041549. https:\/\/doi.org\/10.1101\/cshperspect.a041549.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"776_CR97","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang CH, Qiu J, O\u2019Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162:1229\u201341. https:\/\/doi.org\/10.1016\/j.cell.2015.08.016.","journal-title":"Cell"},{"key":"776_CR98","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.3390\/nu17111891","volume":"17","author":"AE Watson","year":"2025","unstructured":"Watson AE, Yusuf N. The influence of dietary factors on melanoma development and progression: a comprehensive review. Nutrients. 2025;17:1891.","journal-title":"Nutrients"},{"key":"776_CR99","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41568-024-00786-4","volume":"25","author":"P Altea-Manzano","year":"2025","unstructured":"Altea-Manzano P, Decker-Farrell A, Janowitz T, Erez A. Metabolic interplays between the tumour and the host shape the tumour macroenvironment. Nat Rev Cancer. 2025;25:274\u201392. https:\/\/doi.org\/10.1038\/s41568-024-00786-4.","journal-title":"Nat Rev Cancer"},{"key":"776_CR100","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-021-00781-x","volume":"19","author":"H Prendeville","year":"2022","unstructured":"Prendeville H, Lynch L. Diet, lipids, and antitumor immunity. Cell Mol Immunol. 2022;19:432\u201344. https:\/\/doi.org\/10.1038\/s41423-021-00781-x.","journal-title":"Cell Mol Immunol"},{"key":"776_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/nu14153245","volume":"14","author":"P Ungaro","year":"2022","unstructured":"Ungaro P, Nettore IC, Franchini F, Palatucci G, Muscogiuri G, Colao A, et al. Epigenome modulation induced by ketogenic diets. Nutrients. 2022;14:3245. https:\/\/doi.org\/10.3390\/nu14153245.","journal-title":"Nutrients"},{"key":"776_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/1743-7075-8-75","volume":"8","author":"RJ Klement","year":"2011","unstructured":"Klement RJ, K\u00e4mmerer U. Is there a role for carbohydrate restriction in the treatment and prevention of cancer? Nutr Metab (Lond). 2011;8:75. https:\/\/doi.org\/10.1186\/1743-7075-8-75.","journal-title":"Nutr Metab (Lond)"},{"key":"776_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/nu14183851","volume":"14","author":"S Dal Bello","year":"2022","unstructured":"Dal Bello S, Valdemarin F, Martinuzzi D, Filippi F, Gigli GL, Valente M. Ketogenic diet in the treatment of gliomas and glioblastomas. Nutrients. 2022;14:3851. https:\/\/doi.org\/10.3390\/nu14183851.","journal-title":"Nutrients"},{"key":"776_CR104","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.semcancer.2023.05.002","volume":"93","author":"M Lee-Rueckert","year":"2023","unstructured":"Lee-Rueckert M, Canyelles M, Tondo M, Rotllan N, Kovanen PT, Llorente-Cortes V, et al. Obesity-induced changes in cancer cells and their microenvironment: mechanisms and therapeutic perspectives to manage dysregulated lipid metabolism. Semin Cancer Biol. 2023;93:36\u201351. https:\/\/doi.org\/10.1016\/j.semcancer.2023.05.002.","journal-title":"Semin Cancer Biol"},{"key":"776_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1728354","volume":"16","author":"W Liu","year":"2025","unstructured":"Liu W, Wang Z, Li Z, Li S, Shi X, Xu Y, et al. Lipid metabolic reprogramming in the tumor microenvironment and its mechanistic role in immunosuppressive cells. Front Immunol. 2025;16:1728354. https:\/\/doi.org\/10.3389\/fimmu.2025.1728354.","journal-title":"Front Immunol"},{"key":"776_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00558-8","volume":"13","author":"H Wang","year":"2024","unstructured":"Wang H, Yung MM, Xuan Y, Chen F, Chan W, Siu MK, et al. Polyunsaturated fatty acids promote M2-like TAM deposition via dampening RhoA-YAP1 signaling in the ovarian cancer microenvironment. Exp Hematol Oncol. 2024;13:90. https:\/\/doi.org\/10.1186\/s40164-024-00558-8.","journal-title":"Exp Hematol Oncol"},{"key":"776_CR107","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1182\/blood-2018-03-841015","volume":"132","author":"L Li","year":"2018","unstructured":"Li L, Zhang J, Chen J, Xu-Monette ZY, Miao Y, Xiao M, et al. B-cell receptor-mediated NFATc1 activation induces IL-10\/STAT3\/PD-L1 signaling in diffuse large B-cell lymphoma. Blood. 2018;132:1805\u201317. https:\/\/doi.org\/10.1182\/blood-2018-03-841015.","journal-title":"Blood"},{"key":"776_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0308-4","volume":"5","author":"SM Steggerda","year":"2017","unstructured":"Steggerda SM, Bennett MK, Chen J, Emberley E, Huang T, Janes JR, et al. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J Immunother Cancer. 2017;5:101. https:\/\/doi.org\/10.1186\/s40425-017-0308-4.","journal-title":"J Immunother Cancer"},{"key":"776_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.694145","volume":"11","author":"S Bao","year":"2021","unstructured":"Bao S, Jiang X, Jin S, Tu P, Lu J. TGF-\u03b21 induces immune escape by enhancing PD-1 and CTLA-4 expression on T lymphocytes in hepatocellular carcinoma. Front Oncol. 2021;11:694145. https:\/\/doi.org\/10.3389\/fonc.2021.694145.","journal-title":"Front Oncol"},{"key":"776_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01349-6","volume":"15","author":"X Shi","year":"2022","unstructured":"Shi X, Yang J, Deng S, Xu H, Wu D, Zeng Q, et al. TGF-\u03b2 signaling in the tumor metabolic microenvironment and targeted therapies. J Hematol Oncol. 2022;15:135. https:\/\/doi.org\/10.1186\/s13045-022-01349-6.","journal-title":"J Hematol Oncol"},{"key":"776_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.590794","volume":"11","author":"JT Gibson","year":"2020","unstructured":"Gibson JT, Orlandella RM, Turbitt WJ, Behring M, Manne U, Sorge RE, et al. Obesity-associated myeloid-derived suppressor cells promote apoptosis of tumor-infiltrating CD8 T cells and immunotherapy resistance in breast cancer. Front Immunol. 2020;11:590794. https:\/\/doi.org\/10.3389\/fimmu.2020.590794.","journal-title":"Front Immunol"},{"key":"776_CR112","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s42255-025-01330-w","volume":"7","author":"B Kunkemoeller","year":"2025","unstructured":"Kunkemoeller B, Prendeville H, McIntyre C, Temesgen A, Loftus RM, Yao C, et al. The source of dietary fat influences anti-tumour immunity in obese mice. Nat Metab. 2025;7:1630\u201345. https:\/\/doi.org\/10.1038\/s42255-025-01330-w.","journal-title":"Nat Metab"},{"key":"776_CR113","doi-asserted-by":"publisher","unstructured":"ang W, Bai Y, Xiong Y, Zhang J, Chen S, Zheng X, et al. Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature. 2016;531:651\u20135. https:\/\/doi.org\/10.1038\/nature17412.","DOI":"10.1038\/nature17412"},{"key":"776_CR114","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/febs.16803","volume":"29","author":"X Li","year":"2024","unstructured":"Li X, Zhang HS. Amino acid metabolism, redox balance and epigenetic regulation in cancer. FEBS J. 2024;29:412\u201329. https:\/\/doi.org\/10.1111\/febs.16803.","journal-title":"FEBS J"},{"key":"776_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06435-w","volume":"15","author":"J Chen","year":"2024","unstructured":"Chen J, Cui L, Lu S, Xu S. Amino acid metabolism in tumor biology and therapy. Cell Death Dis. 2024;15:42. https:\/\/doi.org\/10.1038\/s41419-024-06435-w.","journal-title":"Cell Death Dis"},{"key":"776_CR116","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01760-1","volume":"22","author":"X Liu","year":"2024","unstructured":"Liu X, Ren B, Ren J, Gu M, You L, Zhao Y. The significant role of amino acid metabolic reprogramming in cancer. Cell Commun Signal. 2024;22:380. https:\/\/doi.org\/10.1186\/s12964-024-01760-1.","journal-title":"Cell Commun Signal"},{"key":"776_CR117","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00646-1","volume":"12","author":"H Zhang","year":"2024","unstructured":"Zhang H, Li S, Wang D, Liu S, Xiao T, Gu W, et al. Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment. Biomark Res. 2024;12:96. https:\/\/doi.org\/10.1186\/s40364-024-00646-1.","journal-title":"Biomark Res"},{"key":"776_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1187279","volume":"13","author":"LK Duong","year":"2023","unstructured":"Duong LK, Corbali HI, Riad TS, Ganjoo S, Nanez S, Voss T, et al. Lipid metabolism in tumor immunology and immunotherapy. Front Oncol. 2023;13:1187279. https:\/\/doi.org\/10.3389\/fonc.2023.1187279.","journal-title":"Front Oncol"},{"key":"776_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189259","volume":"1880","author":"L Yang","year":"2025","unstructured":"Yang L, Wang X, Wang S, Shen J, Li Y, Wan S, et al. Targeting lipid metabolism in regulatory T cells for enhancing cancer immunotherapy. Biochim Biophys Acta Rev Cancer. 2025;1880:189259. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189259.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"776_CR120","doi-asserted-by":"publisher","DOI":"10.1172\/JCI148549","volume":"132","author":"MJ Watson","year":"2022","unstructured":"Watson MJ, Delgoffe GM. Fighting in a wasteland: deleterious metabolites and antitumor immunity. J Clin Invest. 2022;132:e148549. https:\/\/doi.org\/10.1172\/JCI148549.","journal-title":"J Clin Invest"},{"key":"776_CR121","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ijc.33781","volume":"150","author":"Y Li","year":"2022","unstructured":"Li Y, Tang J, Jiang J, Chen Z. Metabolic checkpoints and novel approaches for immunotherapy against cancer. Int J Cancer. 2022;150:195\u2013207. https:\/\/doi.org\/10.1002\/ijc.33781.","journal-title":"Int J Cancer"},{"key":"776_CR122","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.trecan.2022.12.006","volume":"9","author":"O Bla\u017eevit\u0161","year":"2023","unstructured":"Bla\u017eevit\u0161 O, Di Tano M, Longo VD. Fasting and fasting mimicking diets in cancer prevention and therapy. Trends Cancer. 2023;9:212\u201322. https:\/\/doi.org\/10.1016\/j.trecan.2022.12.006.","journal-title":"Trends Cancer"},{"key":"776_CR123","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.cmet.2024.06.014","volume":"36","author":"C Vernieri","year":"2024","unstructured":"Vernieri C, Ligorio F, Tripathy D, Longo VD. Cyclic fasting-mimicking diet in cancer treatment: preclinical and clinical evidence. Cell Metab. 2024;36:1644\u201367. https:\/\/doi.org\/10.1016\/j.cmet.2024.06.014.","journal-title":"Cell Metab"},{"key":"776_CR124","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/jcsm.12402","volume":"10","author":"MS Anker","year":"2019","unstructured":"Anker MS, Holcomb R, Muscaritoli M, von Haehling S, Haverkamp W, Jatoi A, et al. Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review. J Cachexia Sarcopenia Muscle. 2019;10:22\u201334. https:\/\/doi.org\/10.1002\/jcsm.12402.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"776_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.189062","volume":"1879","author":"O Menyh\u00e1rt","year":"2024","unstructured":"Menyh\u00e1rt O, Gy\u0151rffy B. Dietary approaches for exploiting metabolic vulnerabilities in cancer. Biochimica et Biophysica Acta (BBA) Rev Cancer. 2024;1879:189062. https:\/\/doi.org\/10.1016\/j.bbcan.2023.189062.","journal-title":"Biochimica et Biophysica Acta (BBA) Rev Cancer"},{"key":"776_CR126","doi-asserted-by":"publisher","unstructured":"Su Z, Liu Y, Xia Z, Rustgi AK, Gu W. An unexpected role for the ketogenic diet in triggering tumor metastasis by modulating BACH1-mediated transcription. Sci Adv. 2024;10:eadm9481. https:\/\/doi.org\/10.1126\/sciadv.adm9481.","DOI":"10.1126\/sciadv.adm9481"},{"key":"776_CR127","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/01635581.2024.2340784","volume":"76","author":"MD Mattes","year":"2024","unstructured":"Mattes MD, Koturbash I, Leung CN, Wen S, Jacobson GM. A phase I trial of a methionine restricted diet with concurrent radiation therapy. Nutr Cancer. 2024;76:463\u20138. https:\/\/doi.org\/10.1080\/01635581.2024.2340784.","journal-title":"Nutr Cancer"},{"key":"776_CR128","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/1750743X.2025.2511472","volume":"17","author":"LD Duong","year":"2025","unstructured":"Duong LD, Lu X. Dietary impacts on prostate cancer immunotherapy. Immunotherapy. 2025;17:525\u201336. https:\/\/doi.org\/10.1080\/1750743X.2025.2511472.","journal-title":"Immunotherapy"},{"key":"776_CR129","doi-asserted-by":"publisher","first-page":"8322","DOI":"10.7150\/thno.62378","volume":"11","author":"Z Li","year":"2021","unstructured":"Li Z, Sun C, Qin Z. Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming. Theranostics. 2021;11:8322\u201336. https:\/\/doi.org\/10.7150\/thno.62378.","journal-title":"Theranostics"},{"key":"776_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2025.156151","volume":"273","author":"D De Leon-Oliva","year":"2025","unstructured":"De Leon-Oliva D, Gonz\u00e1lez-Prieto P, De Castro-Martinez P, Boaru DL, Laguna-Hern\u00e1ndez P, Fraile-Martinez O, et al. Revisiting the biological role of the Warburg effect: evolving perspectives on cancer metabolism. Pathol Res Pract. 2025;273:156151. https:\/\/doi.org\/10.1016\/j.prp.2025.156151.","journal-title":"Pathol Res Pract"},{"key":"776_CR131","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041540","volume":"14","author":"AC Kimmelman","year":"2024","unstructured":"Kimmelman AC, Sherman MH. The role of stroma in cancer metabolism. Cold Spring Harb Perspect Med. 2024;14:a041540. https:\/\/doi.org\/10.1101\/cshperspect.a041540.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"776_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06110-6","volume":"14","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Shen M, Wu L, Yang H, Yao Y, Yang Q, et al. Stromal cells in the tumor microenvironment: accomplices of tumor progression? Cell Death Dis. 2023;14:587. https:\/\/doi.org\/10.1038\/s41419-023-06110-6.","journal-title":"Cell Death Dis"},{"key":"776_CR133","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03510-8","volume":"20","author":"Z Peng","year":"2022","unstructured":"Peng Z, Ye M, Ding H, Feng Z, Hu K. Spatial transcriptomics atlas reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment components in colorectal cancer. J Transl Med. 2022;20:302. https:\/\/doi.org\/10.1186\/s12967-022-03510-8.","journal-title":"J Transl Med"},{"key":"776_CR134","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175897","volume":"134","author":"J Zhou","year":"2024","unstructured":"Zhou J, Gu J, Qian Q, Zhang Y, Huang T, Li X, et al. Lactate supports Treg function and immune balance via MGAT1 effects on N-glycosylation in the mitochondria. J Clin Invest. 2024;134:e175897. https:\/\/doi.org\/10.1172\/JCI175897.","journal-title":"J Clin Invest"},{"key":"776_CR135","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26383","volume":"2","author":"Z Husain","year":"2013","unstructured":"Husain Z, Seth P, Sukhatme VP. Tumor-derived lactate and myeloid-derived suppressor cells: linking metabolism to cancer immunology. Oncoimmunology. 2013;2:e26383. https:\/\/doi.org\/10.4161\/onci.26383.","journal-title":"Oncoimmunology"},{"key":"776_CR136","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1617662","volume":"16","author":"J Luo","year":"2025","unstructured":"Luo J, Xiang X, Gong G, Jiang L. Cancer-associated fibroblast-mediated immune evasion: molecular mechanisms of stromal-immune crosstalk in the tumor microenvironment. Front Immunol. 2025;16:1617662. https:\/\/doi.org\/10.3389\/fimmu.2025.1617662.","journal-title":"Front Immunol"},{"key":"776_CR137","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-19-0644","volume":"10","author":"CX Dominguez","year":"2020","unstructured":"Dominguez CX, M\u00fcller S, Keerthivasan S, Koeppen H, Hung J, Gierke S, et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15+ myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov. 2020;10:232\u201353. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0644.","journal-title":"Cancer Discov"},{"key":"776_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53908-9","volume":"15","author":"A Forsthuber","year":"2024","unstructured":"Forsthuber A, Aschenbrenner B, Korosec A, Jacob T, Annusver K, Krajic N, et al. Cancer-associated fibroblast subtypes modulate the tumor-immune microenvironment and are associated with skin cancer malignancy. Nat Commun. 2024;15:9678. https:\/\/doi.org\/10.1038\/s41467-024-53908-9.","journal-title":"Nat Commun"},{"key":"776_CR139","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.trecan.2023.01.007","volume":"9","author":"L Arpinati","year":"2023","unstructured":"Arpinati L, Scherz-Shouval R. From gatekeepers to providers: regulation of immune functions by cancer-associated fibroblasts. Trends Cancer. 2023;9:421\u201343. https:\/\/doi.org\/10.1016\/j.trecan.2023.01.007.","journal-title":"Trends Cancer"},{"key":"776_CR140","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102969","volume":"12","author":"M Hilmi","year":"2020","unstructured":"Hilmi M, Nicolle R, Bousquet C, Neuzillet C. Cancer-associated fibroblasts: accomplices in the tumor immune evasion. Cancers (Basel). 2020;12:2969. https:\/\/doi.org\/10.3390\/cancers12102969.","journal-title":"Cancers (Basel)"},{"key":"776_CR141","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0770-1","volume":"12","author":"T Liu","year":"2019","unstructured":"Liu T, Han C, Wang S, Fang P, Ma Z, Xu L, et al. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol. 2019;12:86. https:\/\/doi.org\/10.1186\/s13045-019-0770-1.","journal-title":"J Hematol Oncol"},{"key":"776_CR142","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1113378","volume":"14","author":"C Zhang","year":"2023","unstructured":"Zhang C, Fei Y, Wang H, Hu S, Liu C, Hu R, et al. CAFs orchestrates tumor immune microenvironment-a new target in cancer therapy? Front Pharmacol. 2023;14:1113378. https:\/\/doi.org\/10.3389\/fphar.2023.1113378.","journal-title":"Front Pharmacol"},{"key":"776_CR143","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.cell.2011.08.039","volume":"146","author":"M Potente","year":"2011","unstructured":"Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146:873\u201387. https:\/\/doi.org\/10.1016\/j.cell.2011.08.039.","journal-title":"Cell"},{"key":"776_CR144","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217156","volume":"600","author":"Z Kooshan","year":"2024","unstructured":"Kooshan Z, C\u00e1rdenas-Piedra L, Clements J, Batra J. Glycolysis, the sweet appetite of the tumor microenvironment. Cancer Lett. 2024;600:217156. https:\/\/doi.org\/10.1016\/j.canlet.2024.217156.","journal-title":"Cancer Lett"},{"key":"776_CR145","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41388-024-03228-5","volume":"44","author":"K Kane","year":"2025","unstructured":"Kane K, Edwards D, Chen J. The influence of endothelial metabolic reprogramming on the tumor microenvironment. Oncogene. 2025;44:51\u201363. https:\/\/doi.org\/10.1038\/s41388-024-03228-5.","journal-title":"Oncogene"},{"key":"776_CR146","doi-asserted-by":"publisher","DOI":"10.1186\/2049-3002-2-19","volume":"2","author":"D Verdegem","year":"2014","unstructured":"Verdegem D, Moens S, Stapor P, Carmeliet P. Endothelial cell metabolism: parallels and divergences with cancer cell metabolism. Cancer Metab. 2014;2:19. https:\/\/doi.org\/10.1186\/2049-3002-2-19.","journal-title":"Cancer Metab"},{"key":"776_CR147","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jare.2024.05.001","volume":"70","author":"Y Liu","year":"2025","unstructured":"Liu Y, Wu Z, Li Y, Chen Y, Zhao X, Wu M, et al. Metabolic reprogramming and interventions in angiogenesis. J Adv Res. 2025;70:323\u201338. https:\/\/doi.org\/10.1016\/j.jare.2024.05.001.","journal-title":"J Adv Res"},{"key":"776_CR148","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1146\/annurev-physiol-020518-114731","volume":"81","author":"X Li","year":"2019","unstructured":"Li X, Kumar A, Carmeliet P. Metabolic pathways fueling the endothelial cell drive. Annu Rev Physiol. 2019;81:483\u2013503. https:\/\/doi.org\/10.1146\/annurev-physiol-020518-114731.","journal-title":"Annu Rev Physiol"},{"key":"776_CR149","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10555-019-09799-0","volume":"38","author":"S Pastorekova","year":"2019","unstructured":"Pastorekova S, Gillies RJ. The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev. 2019;38:65\u201377. https:\/\/doi.org\/10.1007\/s10555-019-09799-0.","journal-title":"Cancer Metastasis Rev"},{"key":"776_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111798","volume":"141","author":"X Hao","year":"2021","unstructured":"Hao X, Ren Y, Feng M, Wang Q, Wang Y. Metabolic reprogramming due to hypoxia in pancreatic cancer: implications for tumor formation, immunity, and more. Biomed Pharmacother. 2021;141:111798. https:\/\/doi.org\/10.1016\/j.biopha.2021.111798.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"776_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0061-0","volume":"9","author":"MB Schaaf","year":"2018","unstructured":"Schaaf MB, Garg AD, Agostinis P. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death Dis. 2018;9(2):115. https:\/\/doi.org\/10.1038\/s41419-017-0061-0.","journal-title":"Cell Death Dis"},{"key":"776_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2511-3","volume":"11","author":"S Liu","year":"2020","unstructured":"Liu S, Qin T, Liu Z, Wang J, Jia Y, Feng Y, et al. Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis. 2020;11:309. https:\/\/doi.org\/10.1038\/s41419-020-2511-3.","journal-title":"Cell Death Dis"},{"key":"776_CR153","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1615\/CritRevImmunol.2020033492","volume":"40","author":"S Chouaib","year":"2020","unstructured":"Chouaib S. The antitumor cytotoxic response: If the killer cells play the music, the microenvironmental hypoxia plays the tune. Crit Rev Immunol. 2020;40:157\u201366. https:\/\/doi.org\/10.1615\/CritRevImmunol.2020033492.","journal-title":"Crit Rev Immunol"},{"key":"776_CR154","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.808859","volume":"10","author":"M Jin","year":"2022","unstructured":"Jin M, Cao W, Chen B, Xiong M, Cao G. Tumor-derived lactate creates a favorable niche for tumor via supplying energy source for tumor and modulating the tumor microenvironment. Front Cell Dev Biol. 2022;10:808859. https:\/\/doi.org\/10.3389\/fcell.2022.808859.","journal-title":"Front Cell Dev Biol"},{"key":"776_CR155","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00519-1","volume":"13","author":"Z Shi","year":"2024","unstructured":"Shi Z, Hu C, Zheng X, Sun C, Li Q. Feedback loop between hypoxia and energy metabolic reprogramming aggravates the radioresistance of cancer cells. Exp Hematol Oncol. 2024;13:55. https:\/\/doi.org\/10.1186\/s40164-024-00519-1.","journal-title":"Exp Hematol Oncol"},{"key":"776_CR156","doi-asserted-by":"publisher","first-page":"6901","DOI":"10.2147\/OTT.S172042","volume":"11","author":"JB Wu","year":"2018","unstructured":"Wu JB, Tang YL, Liang XH. Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy. Onco Targets Ther. 2018;11:6901\u20139. https:\/\/doi.org\/10.2147\/OTT.S172042.","journal-title":"Onco Targets Ther"},{"key":"776_CR157","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41568-024-00736-0","volume":"24","author":"S Guelfi","year":"2024","unstructured":"Guelfi S, Hodivala-Dilke K, Bergers G. Targeting the tumour vasculature: from vessel destruction to promotion. Nat Rev Cancer. 2024;24:655\u201375. https:\/\/doi.org\/10.1038\/s41568-024-00736-0.","journal-title":"Nat Rev Cancer"},{"key":"776_CR158","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.719836","volume":"11","author":"T Yang","year":"2021","unstructured":"Yang T, Xiao H, Liu X, Wang Z, Zhang Q, Wei N, et al. Vascular normalization: a new window opened for cancer therapies. Front Oncol. 2021;11:719836. https:\/\/doi.org\/10.3389\/fonc.2021.719836.","journal-title":"Front Oncol"},{"key":"776_CR159","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/s41416-023-02437-1","volume":"129","author":"P Brest","year":"2023","unstructured":"Brest P, Mograbi B, Pag\u00e8s G, Hofman P, Milano G. Checkpoint inhibitors and anti-angiogenic agents: a winning combination. Br J Cancer. 2023;129:1367\u201372. https:\/\/doi.org\/10.1038\/s41416-023-02437-1.","journal-title":"Br J Cancer"},{"key":"776_CR160","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01751-7","volume":"25","author":"NS Sherafat","year":"2025","unstructured":"Sherafat NS, Keshavarz A, Mardi A, Mohammadiara A, Aghaei M, Aghebati-Maleki L, et al. Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective. Clin Exp Med. 2025;25:238. https:\/\/doi.org\/10.1007\/s10238-025-01751-7.","journal-title":"Clin Exp Med"},{"key":"776_CR161","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1158\/0008-5472.CAN-13-2034","volume":"74","author":"JR Doherty","year":"2014","unstructured":"Doherty JR, Yang C, Scott KE, Cameron MD, Fallahi M, Li W, et al. Blocking lactate export by inhibiting the Myc target MCT1 disables glycolysis and glutathione synthesis. Cancer Res. 2014;74:908\u201320. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2034.","journal-title":"Cancer Res"},{"key":"776_CR162","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00784-0","volume":"13","author":"Y Yang","year":"2025","unstructured":"Yang Y, Zhu L, Xu Y, Liang L, Liu L, Chen X, et al. The progress and prospects of targeting the adenosine pathway in cancer immunotherapy. Biomark Res. 2025;13:75. https:\/\/doi.org\/10.1186\/s40364-025-00784-0.","journal-title":"Biomark Res"},{"key":"776_CR163","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00868-x","volume":"7","author":"S Jin","year":"2022","unstructured":"Jin S, Sun Y, Liang X, Gu X, Ning J, Xu Y, et al. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther. 2022;7:39. https:\/\/doi.org\/10.1038\/s41392-021-00868-x.","journal-title":"Signal Transduct Target Ther"},{"key":"776_CR164","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2147\/BCTT.S449510","volume":"16","author":"S Wang","year":"2024","unstructured":"Wang S, Chen Y, Li W, Hao C, Zhang L, Zhao W, et al. Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients. Breast Cancer (Dove Med Press). 2024;16:163\u201379. https:\/\/doi.org\/10.2147\/BCTT.S449510.","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"1","key":"776_CR165","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16212-w","volume":"11","author":"R Vander Velde","year":"2020","unstructured":"Vander Velde R, Yoon N, Marusyk V, Durmaz A, Dhawan A, Miroshnychenko D, et al. Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures. Nat Commun. 2020;11(1):2393. https:\/\/doi.org\/10.1038\/s41467-020-16212-w.","journal-title":"Nat Commun"},{"key":"776_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113064","volume":"150","author":"X Li","year":"2022","unstructured":"Li X, Li M, Huang M, Lin Q, Fang Q, Liu J, et al. The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine. Biomed Pharmacother. 2022;150:113064. https:\/\/doi.org\/10.1016\/j.biopha.2022.113064.","journal-title":"Biomed Pharmacother"},{"key":"776_CR167","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.181","volume":"3","author":"GH Liu","year":"2022","unstructured":"Liu GH, Chen T, Zhang X, Ma XL, Shi HS. Small molecule inhibitors targeting the cancers. MedComm. 2022;3:e181. https:\/\/doi.org\/10.1002\/mco2.181.","journal-title":"MedComm"},{"key":"776_CR168","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6:201. https:\/\/doi.org\/10.1038\/s41392-021-00572-w.","journal-title":"Signal Transduct Target Ther"},{"key":"776_CR169","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/2159-8290.CD-15-0507","volume":"5","author":"ZE Stine","year":"2015","unstructured":"Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, metabolism, and cancer. Cancer Discov. 2015;5:1024\u201339. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0507.","journal-title":"Cancer Discov"},{"key":"776_CR170","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s43018-021-00184-x","volume":"2","author":"S Mukhopadhyay","year":"2021","unstructured":"Mukhopadhyay S, Vander Heiden MG, McCormick F. The metabolic landscape of RAS-driven cancers from biology to therapy. Nat Cancer. 2021;2:271\u201383. https:\/\/doi.org\/10.1038\/s43018-021-00184-x.","journal-title":"Nat Cancer"},{"key":"776_CR171","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.7150\/ijbs.89942","volume":"20","author":"F Fontana","year":"2024","unstructured":"Fontana F, Giannitti G, Marchesi S, Limonta P. The PI3K\/Akt pathway and glucose metabolism: a dangerous liaison in cancer. Int J Biol Sci. 2024;20:3113\u201325. https:\/\/doi.org\/10.7150\/ijbs.89942.","journal-title":"Int J Biol Sci"},{"key":"776_CR172","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/jmcb\/mjy070","volume":"11","author":"J Liu","year":"2019","unstructured":"Liu J, Zhang C, Hu W, Feng Z. Tumor suppressor p53 and metabolism. J Mol Cell Biol. 2019;11:284\u201392. https:\/\/doi.org\/10.1093\/jmcb\/mjy070.","journal-title":"J Mol Cell Biol"},{"key":"776_CR173","doi-asserted-by":"publisher","first-page":"9519","DOI":"10.1074\/jbc.m010144200","volume":"276","author":"C Chen","year":"2001","unstructured":"Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. J Biol Chem. 2001;276:9519\u201325. https:\/\/doi.org\/10.1074\/jbc.m010144200.","journal-title":"J Biol Chem"},{"key":"776_CR174","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02082-x","volume":"10","author":"J Chen","year":"2025","unstructured":"Chen J, Huang Z, Chen Y, Tian H, Chai P, Shen Y, et al. Lactate and lactylation in cancer. Signal Transduct Target Ther. 2025;10:38. https:\/\/doi.org\/10.1038\/s41392-024-02082-x.","journal-title":"Signal Transduct Target Ther"},{"key":"776_CR175","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2017.06.09","volume":"5","author":"I Arozarena","year":"2017","unstructured":"Arozarena I, Wellbrock C. Overcoming resistance to BRAF inhibitors. Ann Transl Med. 2017;5:387. https:\/\/doi.org\/10.21037\/atm.2017.06.09.","journal-title":"Ann Transl Med"},{"key":"776_CR176","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.694","volume":"5","author":"X Ou","year":"2024","unstructured":"Ou X, Gao G, Habaz IA, Wang Y. Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies. MedComm. 2024;5:e694. https:\/\/doi.org\/10.1002\/mco2.694.","journal-title":"MedComm"},{"key":"776_CR177","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.bcp.2014.02.018","volume":"89","author":"L Quintieri","year":"2014","unstructured":"Quintieri L, Selmy M, Indraccolo S. Metabolic effects of antiangiogenic drugs in tumors: therapeutic implications. Biochem Pharmacol. 2014;89:162\u201370. https:\/\/doi.org\/10.1016\/j.bcp.2014.02.018.","journal-title":"Biochem Pharmacol"},{"key":"776_CR178","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1182\/blood-2005-05-1795","volume":"107","author":"E Gottfried","year":"2006","unstructured":"Gottfried E, Kunz-Schughart LA, Ebner S, Mueller-Klieser W, Hoves S, Andreesen R, et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood. 2006;107:2013\u201321. https:\/\/doi.org\/10.1182\/blood-2005-05-1795.","journal-title":"Blood"},{"key":"776_CR179","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","volume":"109","author":"K Fischer","year":"2007","unstructured":"Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109:3812\u20139. https:\/\/doi.org\/10.1182\/blood-2006-07-035972.","journal-title":"Blood"},{"key":"776_CR180","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3892\/ijo.2011.1055","volume":"39","author":"K Goetze","year":"2011","unstructured":"Goetze K, Walenta S, Ksiazkiewicz M, Kunz-Schughart LA, Mueller-Klieser W. Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release. Int J Oncol. 2011;39:453\u201363. https:\/\/doi.org\/10.3892\/ijo.2011.1055.","journal-title":"Int J Oncol"},{"key":"776_CR181","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/ijc.26410","volume":"131","author":"AN Mendler","year":"2012","unstructured":"Mendler AN, Hu B, Prinz PU, Kreutz M, Gottfried E, Noessner E. Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK\/c-Jun activation. Int J Cancer. 2012;131:633\u201340. https:\/\/doi.org\/10.1002\/ijc.26410.","journal-title":"Int J Cancer"},{"key":"776_CR182","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-08023-y","volume":"16","author":"M Zhao","year":"2025","unstructured":"Zhao M, Qian Y, He L, Peng T, Wang H, Wang X, et al. Lactate-mediated histone lactylation promotes melanoma angiogenesis via IL-33\/ST2 axis. Cell Death Dis. 2025;16:701. https:\/\/doi.org\/10.1038\/s41419-025-08023-y.","journal-title":"Cell Death Dis"},{"key":"776_CR183","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188427","volume":"1874","author":"MMG Kes","year":"2020","unstructured":"Kes MMG, Van den Bossche J, Griffioen AW, Huijbers EJM. Oncometabolites lactate and succinate drive pro-angiogenic macrophage response in tumors. Biochim Biophys Acta Rev Cancer. 2020;1874:188427. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188427.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"776_CR184","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1038\/s41418-024-01402-6","volume":"31","author":"L Lanzetti","year":"2024","unstructured":"Lanzetti L. Oncometabolites at the crossroads of genetic, epigenetic and ecological alterations in cancer. Cell Death Differ. 2024;31:1582\u201394. https:\/\/doi.org\/10.1038\/s41418-024-01402-6.","journal-title":"Cell Death Differ"},{"key":"776_CR185","doi-asserted-by":"publisher","DOI":"10.3390\/cells10030678","volume":"10","author":"R Shi","year":"2021","unstructured":"Shi R, Liao C, Zhang Q. Hypoxia-driven effects in cancer: characterization, mechanisms, and therapeutic implications. Cells. 2021;10:678. https:\/\/doi.org\/10.3390\/cells10030678.","journal-title":"Cells"},{"key":"776_CR186","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-024-00682-7","volume":"30","author":"J Zhang","year":"2025","unstructured":"Zhang J, Yao M, Xia S, Zeng F, Liu Q. Systematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer. Cell Mol Biol Lett. 2025;30:2. https:\/\/doi.org\/10.1186\/s11658-024-00682-7.","journal-title":"Cell Mol Biol Lett"},{"key":"776_CR187","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","volume":"29","author":"SA Patel","year":"2023","unstructured":"Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach JV. Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy. Clin Cancer Res. 2023;29:30\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1366.","journal-title":"Clin Cancer Res"},{"key":"776_CR188","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.semcancer.2022.07.005","volume":"86","author":"H Lee","year":"2022","unstructured":"Lee H, Woo SM, Jang H, Kang M, Kim SY. Cancer depends on fatty acids for ATP production: a possible link between cancer and obesity. Semin Cancer Biol. 2022;86:347\u201357. https:\/\/doi.org\/10.1016\/j.semcancer.2022.07.005.","journal-title":"Semin Cancer Biol"},{"key":"776_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2024.156674","volume":"180","author":"Z Wang","year":"2024","unstructured":"Wang Z, Wang M, Guo J, Lu Y, Wei P. Adaptive resistance of tumor cells to anti-vascular endothelial growth factor therapy: a reversible phenomenon. Cytokine. 2024;180:156674. https:\/\/doi.org\/10.1016\/j.cyto.2024.156674.","journal-title":"Cytokine"},{"key":"776_CR190","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.2174\/1389450117666160307143718","volume":"17","author":"S Lord","year":"2016","unstructured":"Lord S, Funes JM, Harris AL, Quintela-Fandino M. Antiangiogenic resistance and cancer metabolism: opportunities for synthetic lethality. Curr Drug Targets. 2016;17:1714\u201327. https:\/\/doi.org\/10.2174\/1389450117666160307143718.","journal-title":"Curr Drug Targets"},{"key":"776_CR191","doi-asserted-by":"publisher","unstructured":"Mollaei M, Hassan ZM, Khorshidi F, Langroudi L. Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells? Transl Oncol. 2021;14:101056. https:\/\/doi.org\/10.1016\/j.tranon.2021.101056.","DOI":"10.1016\/j.tranon.2021.101056"},{"key":"776_CR192","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.tcb.2023.03.003","volume":"33","author":"ES Ali","year":"2023","unstructured":"Ali ES, Ben-Sahra I. Regulation of nucleotide metabolism in cancers and immune disorders. Trends Cell Biol. 2023;33:950\u201366. https:\/\/doi.org\/10.1016\/j.tcb.2023.03.003.","journal-title":"Trends Cell Biol"},{"key":"776_CR193","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082098","volume":"12","author":"TGA Reuvers","year":"2020","unstructured":"Reuvers TGA, Kanaar R, Nonnekens J. DNA damage-inducing anticancer therapies: from global to precision damage. Cancers (Basel). 2020;12:2098. https:\/\/doi.org\/10.3390\/cancers12082098.","journal-title":"Cancers (Basel)"},{"key":"776_CR194","doi-asserted-by":"publisher","DOI":"10.3892\/or.2024.8816","volume":"52","author":"X Weng","year":"2024","unstructured":"Weng X, Zeng WH, Zhong LY, Xie LH, Ge WJ, Lai Z, et al. The molecular mechanisms of chemotherapeutic resistance in tumors (Review). Oncol Rep. 2024;52:157. https:\/\/doi.org\/10.3892\/or.2024.8816.","journal-title":"Oncol Rep"},{"key":"776_CR195","doi-asserted-by":"publisher","first-page":"7296","DOI":"10.1038\/sj.onc.1206935","volume":"22","author":"ZA Rasheed","year":"2003","unstructured":"Rasheed ZA, Rubin EH. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene. 2003;22:7296\u2013304. https:\/\/doi.org\/10.1038\/sj.onc.1206935.","journal-title":"Oncogene"},{"key":"776_CR196","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/bcp.13126","volume":"83","author":"D Bates","year":"2017","unstructured":"Bates D, Eastman A. Microtubule destabilising agents: far more than just antimitotic anticancer drugs. Br J Clin Pharmacol. 2017;83:255\u201368. https:\/\/doi.org\/10.1111\/bcp.13126.","journal-title":"Br J Clin Pharmacol"},{"key":"776_CR197","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-01657-2","volume":"29","author":"P Sati","year":"2024","unstructured":"Sati P, Sharma E, Dhyani P, Attri DC, Rana R, Kiyekbayeva L, et al. Paclitaxel and its semi-synthetic derivatives: comprehensive insights into chemical structure, mechanisms of action, and anticancer properties. Eur J Med Res. 2024;29:90. https:\/\/doi.org\/10.1186\/s40001-024-01657-2.","journal-title":"Eur J Med Res"},{"key":"776_CR198","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1097\/FPC.0b013e3283335277","volume":"19","author":"C Oshiro","year":"2009","unstructured":"Oshiro C, Marsh S, McLeod H, Carrillo MW, Klein T, Altman R. Taxane pathway. Pharmacogenet Genomics. 2009;19:979\u201383. https:\/\/doi.org\/10.1097\/FPC.0b013e3283335277.","journal-title":"Pharmacogenet Genomics"},{"key":"776_CR199","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02624-9","volume":"22","author":"P Dhyani","year":"2022","unstructured":"Dhyani P, Quispe C, Sharma E, Bahukhandi A, Sati P, Attri DC, et al. Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine. Cancer Cell Int. 2022;22:206. https:\/\/doi.org\/10.1186\/s12935-022-02624-9.","journal-title":"Cancer Cell Int"},{"key":"776_CR200","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.691795","volume":"8","author":"L Wang","year":"2021","unstructured":"Wang L, Zhao X, Fu J, Xu W, Yuan J. The role of tumor metabolism in cisplatin resistance. Front Mol Biosci. 2021;8:691795. https:\/\/doi.org\/10.3389\/fmolb.2021.691795.","journal-title":"Front Mol Biosci"},{"key":"776_CR201","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101223","volume":"81","author":"GL Beretta","year":"2025","unstructured":"Beretta GL, Cassinelli G, Rossi G, Azzariti A, Corbeau I, Tosi D, et al. Novel insights into taxane pharmacology: an update on drug resistance mechanisms, immunomodulation and drug delivery strategies. Drug Resist Updat. 2025;81:101223. https:\/\/doi.org\/10.1016\/j.drup.2025.101223.","journal-title":"Drug Resist Updat"},{"key":"776_CR202","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120649","volume":"10","author":"DR Minton","year":"2015","unstructured":"Minton DR, Fu L, Chen Q, Robinson BD, Gross SS, Nanus DM, et al. Analyses of the transcriptome and metabolome demonstrate that HIF1\u03b1 mediates altered tumor metabolism in clear cell renal cell carcinoma. PLoS ONE. 2015;10:e0120649. https:\/\/doi.org\/10.1371\/journal.pone.0120649.","journal-title":"PLoS ONE"},{"key":"776_CR203","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.trecan.2022.05.005","volume":"8","author":"A Mittal","year":"2022","unstructured":"Mittal A, Nenwani M, Sarangi I, Achreja A, Lawrence TS, Nagrath D. Radiotherapy-induced metabolic hallmarks in the tumor microenvironment. Trends Cancer. 2022;8:855\u201369. https:\/\/doi.org\/10.1016\/j.trecan.2022.05.005.","journal-title":"Trends Cancer"},{"key":"776_CR204","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0758-7","volume":"37","author":"L Tang","year":"2018","unstructured":"Tang L, Wei F, Wu Y, He Y, Shi L, Xiong F, et al. Role of metabolism in cancer cell radioresistance and radiosensitization methods. J Exp Clin Cancer Res. 2018;37:87. https:\/\/doi.org\/10.1186\/s13046-018-0758-7.","journal-title":"J Exp Clin Cancer Res"},{"key":"776_CR205","doi-asserted-by":"publisher","DOI":"10.1186\/s40169-016-0110-9","volume":"5","author":"C Herbel","year":"2016","unstructured":"Herbel C, Patsoukis N, Bardhan K, Seth P, Weaver JD, Boussiotis VA. Clinical significance of T cell metabolic reprogramming in cancer. Clin Transl Med. 2016;5:29. https:\/\/doi.org\/10.1186\/s40169-016-0110-9.","journal-title":"Clin Transl Med"},{"key":"776_CR206","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1111\/cas.15497","volume":"113","author":"J Nagasaki","year":"2022","unstructured":"Nagasaki J, Ishino T, Togashi Y. Mechanisms of resistance to immune checkpoint inhibitors. Cancer Sci. 2022;113:3303\u201312. https:\/\/doi.org\/10.1111\/cas.15497.","journal-title":"Cancer Sci"},{"key":"776_CR207","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.pharmthera.2018.11.004","volume":"195","author":"R Ramapriyan","year":"2019","unstructured":"Ramapriyan R, Caetano MS, Barsoumian HB, Mafra ACP, Zambalde EP, Menon H, et al. Altered cancer metabolism in mechanisms of immunotherapy resistance. Pharmacol Ther. 2019;195:162\u201371. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.11.004.","journal-title":"Pharmacol Ther"},{"key":"776_CR208","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06956-5","volume":"20","author":"S Wang","year":"2020","unstructured":"Wang S, Wu J, Shen H, Wang J. The prognostic value of IDO expression in solid tumors: a systematic review and meta-analysis. BMC Cancer. 2020;20:471. https:\/\/doi.org\/10.1186\/s12885-020-06956-5.","journal-title":"BMC Cancer"},{"key":"776_CR209","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000492849","volume":"49","author":"CP Yu","year":"2018","unstructured":"Yu CP, Fu SF, Chen X, Ye J, Ye Y, Kong LD, et al. The clinicopathological and prognostic significance of IDO1 expression in human solid tumors: evidence from a systematic review and meta-analysis. Cell Physiol Biochem. 2018;49:134\u201343. https:\/\/doi.org\/10.1159\/000492849.","journal-title":"Cell Physiol Biochem"},{"key":"776_CR210","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1158\/1078-0432.CCR-24-4264","volume":"31","author":"PD Zang","year":"2025","unstructured":"Zang PD, Dorff TB. IDO believe in immunotherapy. Clin Cancer Res. 2025;31:2077\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-4264.","journal-title":"Clin Cancer Res"},{"key":"776_CR211","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2019.06.021","volume":"65","author":"SM Toor","year":"2020","unstructured":"Toor SM, Sasidharan Nair V, Decock J, Elkord E. Immune checkpoints in the tumor microenvironment. Semin Cancer Biol. 2020;65:1\u201312. https:\/\/doi.org\/10.1016\/j.semcancer.2019.06.021.","journal-title":"Semin Cancer Biol"},{"key":"776_CR212","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01469","volume":"11","author":"R Saleh","year":"2020","unstructured":"Saleh R, Toor SM, Sasidharan Nair V, Elkord E. Role of epigenetic modifications in inhibitory immune checkpoints in cancer development and progression. Front Immunol. 2020;11:1469. https:\/\/doi.org\/10.3389\/fimmu.2020.01469.","journal-title":"Front Immunol"},{"key":"776_CR213","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/0008-5472.CAN-21-4370","volume":"82","author":"RDZ Mullins","year":"2022","unstructured":"Mullins RDZ, Pal A, Barrett TF, Heft Neal ME, Puram SV. Epithelial-mesenchymal plasticity in tumor immune evasion. Cancer Res. 2022;82:2329\u201343. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-4370.","journal-title":"Cancer Res"},{"key":"776_CR214","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102461","volume":"110","author":"Y Fujiwara","year":"2022","unstructured":"Fujiwara Y, Kato S, Nesline MK, Conroy JM, DePietro P, Pabla S, et al. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy. Cancer Treat Rev. 2022;110:102461. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102461.","journal-title":"Cancer Treat Rev"},{"key":"776_CR215","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-025-10253-7","volume":"44","author":"A Suraweera","year":"2025","unstructured":"Suraweera A, Byrne KJ, Richard DJ. Epigenetic drugs in cancer therapy. Cancer Metastasis Rev. 2025;44:37. https:\/\/doi.org\/10.1007\/s10555-025-10253-7.","journal-title":"Cancer Metastasis Rev"},{"key":"776_CR216","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrd3955","volume":"12","author":"JF Chen","year":"2013","unstructured":"Chen JF, Eltzschig HK, Fredholm BB. Adenosine receptors as drug targets--what are the challenges? Nat Rev Drug Discov. 2013;12:265\u201386. https:\/\/doi.org\/10.1038\/nrd3955.","journal-title":"Nat Rev Drug Discov"},{"key":"776_CR217","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9:274. https:\/\/doi.org\/10.1038\/s41392-024-01979-x.","journal-title":"Signal Transduct Target Ther"},{"key":"776_CR218","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0789-z","volume":"21","author":"P Strati","year":"2019","unstructured":"Strati P, Neelapu SS. Chimeric antigen receptor-engineered T cell therapy in lymphoma. Curr Oncol Rep. 2019;21:38. https:\/\/doi.org\/10.1007\/s11912-019-0789-z.","journal-title":"Curr Oncol Rep"},{"key":"776_CR219","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev-chembioeng-092120-092914","volume":"13","author":"TA Gao","year":"2022","unstructured":"Gao TA, Chen YY. Engineering next-generation CAR-T cells: overcoming tumor hypoxia and metabolism. Annu Rev Chem Biomol Eng. 2022;13:193\u2013216. https:\/\/doi.org\/10.1146\/annurev-chembioeng-092120-092914.","journal-title":"Annu Rev Chem Biomol Eng"},{"key":"776_CR220","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jtct.2023.04.007","volume":"29","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Jain MD, Smith EL. Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma. Transplant Cell Ther. 2023;29:418\u201328. https:\/\/doi.org\/10.1016\/j.jtct.2023.04.007.","journal-title":"Transplant Cell Ther"},{"key":"776_CR221","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/1744666X.2024.2380894","volume":"20","author":"CA Taylor","year":"2024","unstructured":"Taylor CA, Glover M, Maher J. CAR-T cell technologies that interact with the tumour microenvironment in solid tumours. Expert Rev Clin Immunol. 2024;20:849\u201371. https:\/\/doi.org\/10.1080\/1744666X.2024.2380894.","journal-title":"Expert Rev Clin Immunol"},{"key":"776_CR222","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.177141","volume":"9","author":"R Hatae","year":"2024","unstructured":"Hatae R, Kyewalabye K, Yamamichi A, Chen T, Phyu S, Chuntova P, et al. Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment. JCI Insight. 2024;9:e177141. https:\/\/doi.org\/10.1172\/jci.insight.177141.","journal-title":"JCI Insight"},{"issue":"2","key":"776_CR223","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, O\u2019Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44(2):380\u201390. https:\/\/doi.org\/10.1016\/j.immuni.2016.01.021.","journal-title":"Immunity"},{"key":"776_CR224","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23331-5","volume":"12","author":"L Giuffrida","year":"2021","unstructured":"Giuffrida L, Sek K, Henderson MA, Lai J, Chen AXY, Meyran D, et al. CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nat Commun. 2021;12:3236. https:\/\/doi.org\/10.1038\/s41467-021-23331-5.","journal-title":"Nat Commun"},{"key":"776_CR225","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","volume":"125","author":"S Ninomiya","year":"2015","unstructured":"Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, et al. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015;125:3905\u201316. https:\/\/doi.org\/10.1182\/blood-2015-01-621474.","journal-title":"Blood"},{"key":"776_CR226","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.medj.2024.03.001","volume":"5","author":"J Liu","year":"2024","unstructured":"Liu J, Jiao X, Ma D, Fang Y, Gao Q. CAR-T therapy and targeted treatments: emerging combination strategies in solid tumors. Med. 2024;5:530\u201349. https:\/\/doi.org\/10.1016\/j.medj.2024.03.001.","journal-title":"Med"},{"key":"776_CR227","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1016\/j.ymthe.2024.07.020","volume":"32","author":"N Li","year":"2024","unstructured":"Li N, Rodriguez JL, Yin Y, Logun MT, Zhang L, Yu S, et al. Armored bicistronic CAR T cells with dominant-negative TGF-\u03b2 receptor II to overcome resistance in glioblastoma. Mol Ther. 2024;32:3522\u201338. https:\/\/doi.org\/10.1016\/j.ymthe.2024.07.020.","journal-title":"Mol Ther"},{"key":"776_CR228","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01574-6","volume":"25","author":"R Shaik","year":"2025","unstructured":"Shaik R, Royyala SA, Inapanuri B, Durgam A, Khan H, Unnisa A. Tumor infiltration therapy: from FDA approval to next-generation approaches. Clin Exp Med. 2025;25:254. https:\/\/doi.org\/10.1007\/s10238-025-01574-6.","journal-title":"Clin Exp Med"},{"key":"776_CR229","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62263-2","volume":"16","author":"M Maffezzini","year":"2025","unstructured":"Maffezzini M, Musio S, Di Ianni N, Rumolo A, Patan\u00e8 M, Galluzzo A, et al. Polyclonal expansion of functional tumor-reactive lymphocytes infiltrating glioblastoma for personalized cell therapy. Nat Commun. 2025;16:7279. https:\/\/doi.org\/10.1038\/s41467-025-62263-2.","journal-title":"Nat Commun"},{"key":"776_CR230","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03793-4","volume":"73","author":"S Matsueda","year":"2024","unstructured":"Matsueda S, Chen L, Li H, Yao H, Yu F. Recent clinical researches and technological development in TIL therapy. Cancer Immunol Immunother. 2024;73:232. https:\/\/doi.org\/10.1007\/s00262-024-03793-4.","journal-title":"Cancer Immunol Immunother"},{"key":"776_CR231","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.cels.2024.11.010","volume":"15","author":"B Feng","year":"2024","unstructured":"Feng B, Li R, Li W, Tang L. Metabolic immunoengineering approaches to enhance CD8+ T cell-based cancer immunotherapy. Cell Syst. 2024;15:1225\u201344. https:\/\/doi.org\/10.1016\/j.cels.2024.11.010.","journal-title":"Cell Syst"},{"key":"776_CR232","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1158\/0008-5472.CAN-14-2277","volume":"75","author":"JG Crompton","year":"2015","unstructured":"Crompton JG, Sukumar M, Roychoudhuri R, Clever D, Gros A, Eil RL, et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res. 2015;75:296\u2013305. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-2277.","journal-title":"Cancer Res"},{"key":"776_CR233","doi-asserted-by":"publisher","unstructured":"Chen C, Zheng H, Horwitz EM, Ando S, Araki K, Zhao P, et al. Mitochondrial metabolic flexibility is critical for CD8+ T cell antitumor immunity. Sci Adv. 2023 Dec 8;9:eadf9522. https:\/\/doi.org\/10.1126\/sciadv.adf9522.","DOI":"10.1126\/sciadv.adf9522"},{"key":"776_CR234","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1488565","volume":"7","author":"CM Mousset","year":"2018","unstructured":"Mousset CM, Hobo W, Ji Y, Fredrix H, De Giorgi V, Allison RD, et al. Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8+ T cells for adoptive immunotherapy. Oncoimmunology. 2018;7:e1488565. https:\/\/doi.org\/10.1080\/2162402X.2018.1488565.","journal-title":"Oncoimmunology"},{"key":"776_CR235","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104671","volume":"209","author":"U Mony","year":"2025","unstructured":"Mony U, Veeraraghavan VP. Outcomes of tumor-infiltrating lymphocyte therapy in solid tumours\u2014a systematic review and meta analysis. Crit Rev Oncol Hematol. 2025;209:104671. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104671.","journal-title":"Crit Rev Oncol Hematol"},{"key":"776_CR236","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.ccell.2018.03.005","volume":"33","author":"R Zappasodi","year":"2018","unstructured":"Zappasodi R, Merghoub T, Wolchok JD. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell. 2018;33:581\u201398. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.005.","journal-title":"Cancer Cell"},{"key":"776_CR237","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS. CAR T cells and T-cell therapies for cancer: a translational science review. JAMA. 2024;332:1924\u201335. https:\/\/doi.org\/10.1001\/jama.2024.19462.","journal-title":"JAMA"},{"key":"776_CR238","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00490-x","volume":"13","author":"Z Liu","year":"2024","unstructured":"Liu Z, Lei W, Wang H, Liu X, Fu R. Challenges and strategies associated with CAR-T cell therapy in blood malignancies. Exp Hematol Oncol. 2024;13:22. https:\/\/doi.org\/10.1186\/s40164-024-00490-x.","journal-title":"Exp Hematol Oncol"},{"key":"776_CR239","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00535-1","volume":"13","author":"A Van der Vreken","year":"2024","unstructured":"Van der Vreken A, Vanderkerken K, De Bruyne E, De Veirman K, Breckpot K, Menu E. Fueling CARs: metabolic strategies to enhance CAR T-cell therapy. Exp Hematol Oncol. 2024;13:66. https:\/\/doi.org\/10.1186\/s40164-024-00535-1.","journal-title":"Exp Hematol Oncol"},{"key":"776_CR240","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00575-7","volume":"13","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Zheng J, Lu Y, Mai Z, Lin Y, Lin P, et al. Optimizing CD8+ T cell-based immunotherapy via metabolic interventions: a comprehensive review of intrinsic and extrinsic modulators. Exp Hematol Oncol. 2024;13:103. https:\/\/doi.org\/10.1186\/s40164-024-00575-7.","journal-title":"Exp Hematol Oncol"},{"key":"776_CR241","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1688995","volume":"16","author":"T Frlic","year":"2025","unstructured":"Frlic T, Pavlin M. Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy. Front Immunol. 2025;16:1688995. https:\/\/doi.org\/10.3389\/fimmu.2025.1688995.","journal-title":"Front Immunol"},{"key":"776_CR242","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2025.1002297","volume":"6","author":"L Cabez\u00f3n-Guti\u00e9rrez","year":"2025","unstructured":"Cabez\u00f3n-Guti\u00e9rrez L, Palka-Kotlowska M, Custodio-Cabello S, Chac\u00f3n-Ovejero B, Pacheco-Barcia V. Metabolic mechanisms of immunotherapy resistance. Explor Target Antitumor Ther. 2025;6:1002297. https:\/\/doi.org\/10.37349\/etat.2025.1002297.","journal-title":"Explor Target Antitumor Ther"},{"key":"776_CR243","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2022","unstructured":"Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2022;10:1367\u2013401. https:\/\/doi.org\/10.1016\/j.gendis.2022.02.007.","journal-title":"Genes Dis"},{"key":"776_CR244","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.902117","volume":"10","author":"L Maese","year":"2022","unstructured":"Maese L, Rau RE. Current use of asparaginase in acute lymphoblastic leukemia\/lymphoblastic lymphoma. Front Pediatr. 2022;10:902117. https:\/\/doi.org\/10.3389\/fped.2022.902117.","journal-title":"Front Pediatr"},{"key":"776_CR245","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/0976-500X.184769","volume":"7","author":"RA Egler","year":"2016","unstructured":"Egler RA, Ahuja SP, Matloub Y. L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. J Pharmacol Pharmacother. 2016;7:62\u201371. https:\/\/doi.org\/10.4103\/0976-500X.184769.","journal-title":"J Pharmacol Pharmacother"},{"key":"776_CR246","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1007\/s13311-022-01238-3","volume":"19","author":"JJ Miller","year":"2022","unstructured":"Miller JJ. Targeting IDH-mutant glioma. Neurotherapeutics. 2022;19:1724\u201332. https:\/\/doi.org\/10.1007\/s13311-022-01238-3.","journal-title":"Neurotherapeutics"},{"key":"776_CR247","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01013-5","volume":"9","author":"J Watts","year":"2025","unstructured":"Watts J, Nong T, Micin K, Soong D, Madarang E, Affer M, et al. Functional cure with single agent olutasidenib in relapsed IDH1\/NPM1 co-mutated AML. npj Precis Oncol. 2025;9:211. https:\/\/doi.org\/10.1038\/s41698-025-01013-5.","journal-title":"npj Precis Oncol"},{"key":"776_CR248","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s40265-024-02097-2","volume":"84","author":"YN Lamb","year":"2024","unstructured":"Lamb YN. Vorasidenib: first approval. Drugs. 2024;84:1325\u201331. https:\/\/doi.org\/10.1007\/s40265-024-02097-2.","journal-title":"Drugs"},{"key":"776_CR249","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1182\/bloodadvances.2024014865","volume":"9","author":"A Mina","year":"2025","unstructured":"Mina A, McGraw KL, Cunningham L, Kim N, Jen EY, Calvo KR, et al. Advancing drug development in myelodysplastic syndromes. Blood Adv. 2025;9:1095\u2013104. https:\/\/doi.org\/10.1182\/bloodadvances.2024014865.","journal-title":"Blood Adv"},{"key":"776_CR250","doi-asserted-by":"publisher","first-page":"6336","DOI":"10.1002\/cam4.4182","volume":"10","author":"S de Botton","year":"2021","unstructured":"de Botton S, Brandwein JM, Wei AH, Pigneux A, Quesnel B, Thomas X, et al. Improved survival with enasidenib versus standard of care in relapsed\/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. Cancer Med. 2021;10:6336\u201343. https:\/\/doi.org\/10.1002\/cam4.4182.","journal-title":"Cancer Med"},{"key":"776_CR251","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1158\/1078-0432.CCR-24-2196","volume":"31","author":"AC Woods","year":"2025","unstructured":"Woods AC, Norsworthy KJ, Choe M, Gehrke BJ, Chen H, Vallejo J, et al. FDA approval summary: Olutasidenib for adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 1 mutation. Clin Cancer Res. 2025;31:12\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2196.","journal-title":"Clin Cancer Res"},{"key":"776_CR252","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-024-00135-y","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard A. FDA approves IDH1 and IDH2 inhibitor for brain cancer. Nat Rev Drug Discov. 2024;23:731. https:\/\/doi.org\/10.1038\/d41573-024-00135-y.","journal-title":"Nat Rev Drug Discov"},{"key":"776_CR253","doi-asserted-by":"publisher","first-page":"4412","DOI":"10.1158\/1078-0432.CCR-25-1333","volume":"31","author":"MI Barbato","year":"2025","unstructured":"Barbato MI, Barone AK, Aungst SL, Miller CP, Ananthula S, Bi Y, et al. FDA approval summary: Vorasidenib for IDH-Mutant Grade 2 astrocytoma or oligodendroglioma following surgery. Clin Cancer Res. 2025;31:4412\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-1333.","journal-title":"Clin Cancer Res"},{"key":"776_CR254","doi-asserted-by":"publisher","unstructured":"Winer AJ, do Amaral PS, Ryan EG, Lambrecht MA, Chen CL, Rini BI, et al. The safety profile of belzutifan in renal tumors: real-world data from a tertiary academic center. Oncologist. 2025;30:oyaf274. https:\/\/doi.org\/10.1093\/oncolo\/oyaf274.","DOI":"10.1093\/oncolo\/oyaf274"},{"key":"776_CR255","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251317846","volume":"17","author":"X Wu","year":"2025","unstructured":"Wu X, Lazris D, Wong R, Tykodi SS. Belzutifan for the treatment of renal cell carcinoma. Ther Adv Med Oncol. 2025;17:17588359251317846. https:\/\/doi.org\/10.1177\/17588359251317846.","journal-title":"Ther Adv Med Oncol"},{"key":"776_CR256","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-22-1054","volume":"28","author":"J Fallah","year":"2022","unstructured":"Fallah J, Brave MH, Weinstock C, Mehta GU, Bradford D, Gittleman H, et al. FDA approval summary: Belzutifan for von Hippel-Lindau disease-associated tumors. Clin Cancer Res. 2022;28:4843\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1054.","journal-title":"Clin Cancer Res"},{"key":"776_CR257","unstructured":"Drug Approvals and Databases. Food and Drug Administration (FDA), Silver Spring. 2025. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/resources-information-approved drugs. Accessed 29 Aug 2025."},{"key":"776_CR258","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/neuonc\/noac234","volume":"25","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Nguyen CC, Zhang NT, Fink NS, John JD, Venkatesh OG, et al. Neurological applications of belzutifan in von Hippel-Lindau disease. Neuro Oncol. 2023;25:827\u201338. https:\/\/doi.org\/10.1093\/neuonc\/noac234.","journal-title":"Neuro Oncol"},{"key":"776_CR259","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.cllc.2020.07.012","volume":"21","author":"PE Hall","year":"2020","unstructured":"Hall PE, Ready N, Johnston A, Bomalaski JS, Venhaus RR, Sheaff M, et al. Phase II study of arginine deprivation therapy with pegargiminase in patients with relapsed sensitive or refractory small-cell lung cancer. Clin Lung Cancer. 2020;21:527\u201333. https:\/\/doi.org\/10.1016\/j.cllc.2020.07.012.","journal-title":"Clin Lung Cancer"},{"key":"776_CR260","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104536","volume":"10","author":"MA Gouda","year":"2025","unstructured":"Gouda MA, Voss MH, Tawbi H, Gordon M, Tykodi SS, Lam ET, et al. A phase I\/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer. ESMO Open. 2025;10:104536. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104536.","journal-title":"ESMO Open"},{"key":"776_CR261","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2022.3511","volume":"8","author":"NM Tannir","year":"2022","unstructured":"Tannir NM, Agarwal N, Porta C, Lawrence NJ, Motzer R, McGregor B, et al. Efficacy and safety of telaglenastat plus cabozantinib vs placebo plus cabozantinib in patients with advanced renal cell carcinoma: the CANTATA randomized clinical trial. JAMA Oncol. 2022;8:1411\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2022.3511.","journal-title":"JAMA Oncol"},{"key":"776_CR262","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13046-020-01579-x","volume":"39","author":"L Gao","year":"2020","unstructured":"Gao L, Xu Z, Huang Z, Tang Y, Yang D, Huang J, et al. CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling. J Exp Clin Cancer Res. 2020;39:73. https:\/\/doi.org\/10.1186\/s13046-020-01579-x.","journal-title":"J Exp Clin Cancer Res"},{"key":"776_CR263","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1200\/JCO.23.02659","volume":"42","author":"PA Philip","year":"2024","unstructured":"Philip PA, Sahai V, Bahary N, Mahipal A, Kasi A, Rocha Lima CMS, et al. Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study. J Clin Oncol. 2024;42:3692\u2013701. https:\/\/doi.org\/10.1200\/JCO.23.02659.","journal-title":"J Clin Oncol"},{"key":"776_CR264","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41416-019-0717-x","volume":"122","author":"M Beloueche-Babari","year":"2020","unstructured":"Beloueche-Babari M, Casals Galobart T, Delgado-Goni T, Wantuch S, Parkes HG, Tandy D, et al. Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration. Br J Cancer. 2020;122:895\u2013903. https:\/\/doi.org\/10.1038\/s41416-019-0717-x.","journal-title":"Br J Cancer"},{"key":"776_CR265","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-22-2263","volume":"29","author":"S Halford","year":"2023","unstructured":"Halford S, Veal GJ, Wedge SR, Payne GS, Bacon CM, Sloan P, et al. A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer. Clin Cancer Res. 2023;29:1429\u201339. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2263.","journal-title":"Clin Cancer Res"},{"key":"776_CR266","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100797","volume":"34","author":"G Falchook","year":"2021","unstructured":"Falchook G, Infante J, Arkenau HT, Patel MR, Dean E, Borazanci E, et al. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine. 2021;34:100797. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100797.","journal-title":"EClinicalMedicine"},{"key":"776_CR267","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1021\/acs.jproteome.4c00252","volume":"23","author":"BD Fries","year":"2024","unstructured":"Fries BD, Hummon AB. FAS inhibited proteomics and phosphoproteomics profiling of colorectal cancer spheroids shows activation of ferroptotic death mechanism. J Proteome Res. 2024;23:3904\u201316. https:\/\/doi.org\/10.1021\/acs.jproteome.4c00252.","journal-title":"J Proteome Res"},{"key":"776_CR268","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104910","volume":"214","author":"PV Nuzzo","year":"2025","unstructured":"Nuzzo PV, Rodrigues S, Ribeiro CF, Teixeira IF, Fanelli GN, Bleve S, et al. Targeting cancer metabolism: therapeutic potential of the fatty acid synthase (FASN) inhibitors. Crit Rev Oncol Hematol. 2025;214:104910. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104910.","journal-title":"Crit Rev Oncol Hematol"},{"key":"776_CR269","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ccell.2018.04.011","volume":"34","author":"MS Waitkus","year":"2018","unstructured":"Waitkus MS, Diplas BH, Yan H. Biological role and therapeutic potential of IDH mutations in cancer. Cancer Cell. 2018;34:186\u201395. https:\/\/doi.org\/10.1016\/j.ccell.2018.04.011.","journal-title":"Cancer Cell"},{"key":"776_CR270","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2318843121","volume":"121","author":"W Hua","year":"2024","unstructured":"Hua W, Zhang W, Brown H, Wu J, Fang X, Shahi M, et al. Rapid detection of IDH mutations in gliomas by intraoperative mass spectrometry. Proc Natl Acad Sci U S A. 2024;121:e2318843121. https:\/\/doi.org\/10.1073\/pnas.2318843121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"776_CR271","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102193","volume":"51","author":"Y Wang","year":"2025","unstructured":"Wang Y, Song J, Zheng S, Wang S. Advancements in understanding the molecular mechanisms and clinical implications of Von Hippel-Lindau syndrome: a comprehensive review. Transl Oncol. 2025;51:102193. https:\/\/doi.org\/10.1016\/j.tranon.2024.102193.","journal-title":"Transl Oncol"},{"key":"776_CR272","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/14740338.2024.2448210","volume":"24","author":"Y Fu","year":"2025","unstructured":"Fu Y, Lv R, Li R, Li W, Guo Z. Safety profile of isocitrate dehydrogenase inhibitors in cancer therapy: a pharmacovigilance study of the FDA Adverse Event Reporting System. Expert Opin Drug Saf. 2025;24:479\u201386. https:\/\/doi.org\/10.1080\/14740338.2024.2448210.","journal-title":"Expert Opin Drug Saf"},{"key":"776_CR273","doi-asserted-by":"publisher","unstructured":"Peres T, Aeppli S, Fischer S, Hundsberger T, Rothermundt C. First single-centre experience with the novel HIF-\u03b1 inhibitor belzutifan in Switzerland. Curr Oncol. 2025;32. https:\/\/doi.org\/10.3390\/curroncol32020064.","DOI":"10.3390\/curroncol32020064"},{"key":"776_CR274","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105109","volume":"10","author":"STC Shepherd","year":"2025","unstructured":"Shepherd STC, Kelly-Morland C, Drage S, Brady AF, Macwana R, Pickering L, et al. Fatal intracranial haemorrhage shortly after Belzutifan initiation in Von Hippel-Lindau (VHL) disease-associated haemangioblastoma. ESMO Open. 2025;10:105109. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105109.","journal-title":"ESMO Open"},{"key":"776_CR275","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2217\/fon-2023-0679","volume":"20","author":"L Curry","year":"2024","unstructured":"Curry L, Soleimani M. Belzutifan: a novel therapeutic for the management of Von Hippel-Lindau disease and beyond. Future Oncol. 2024;20:1251\u201366. https:\/\/doi.org\/10.2217\/fon-2023-0679.","journal-title":"Future Oncol"},{"key":"776_CR276","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1182\/bloodadvances.2021005631","volume":"6","author":"LS Lynggaard","year":"2022","unstructured":"Lynggaard LS, Rank CU, Hansen SN, Gottschalk H\u00f8jfeldt S, Henriksen LT, Jarvis KB, et al. Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study. Blood Adv. 2022;6:138\u201347. https:\/\/doi.org\/10.1182\/bloodadvances.2021005631.","journal-title":"Blood Adv"},{"key":"776_CR277","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1001\/jamaoncol.2023.6789","volume":"10","author":"PW Szlosarek","year":"2024","unstructured":"Szlosarek PW, Creelan BC, Sarkodie T, Nolan L, Taylor P, Olevsky O, et al. Pegargiminase plus first-line chemotherapy in patients with nonepithelioid Pleural Mesothelioma: the ATOMIC-Meso randomized clinical trial. JAMA Oncol. 2024;10:475\u201383. https:\/\/doi.org\/10.1001\/jamaoncol.2023.6789.","journal-title":"JAMA Oncol"},{"key":"776_CR278","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007349","volume":"11","author":"N Babl","year":"2023","unstructured":"Babl N, Decking SM, Voll F, Althammer M, Sala-Hojman A, Ferretti R, et al. MCT4 blockade increases the efficacy of immune checkpoint blockade. J Immunother Cancer. 2023;11:e007349. https:\/\/doi.org\/10.1136\/jitc-2023-007349.","journal-title":"J Immunother Cancer"},{"key":"776_CR279","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1158\/1078-0432.CCR-13-2270","volume":"20","author":"R Pola\u0144ski","year":"2014","unstructured":"Pola\u0144ski R, Hodgkinson CL, Fusi A, Nonaka D, Priest L, Kelly P, et al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin Cancer Res. 2014;20:926\u201337. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2270.","journal-title":"Clin Cancer Res"},{"key":"776_CR280","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1158\/1535-7163.MCT-13-1091","volume":"13","author":"BM Bola","year":"2014","unstructured":"Bola BM, Chadwick AL, Michopoulos F, Blount KG, Telfer BA, Williams KJ, et al. Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Mol Cancer Ther. 2014;13:2805\u201316. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-1091.","journal-title":"Mol Cancer Ther"},{"key":"776_CR281","unstructured":"https:\/\/www.clinicaltrials.gov\/."},{"key":"776_CR282","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.1158\/0008-5472.CAN-16-2686","volume":"77","author":"M Beloueche-Babari","year":"2017","unstructured":"Beloueche-Babari M, Wantuch S, Casals Galobart T, Koniordou M, Parkes HG, Arunan V, et al. MCT1 inhibitor AZD3965 increases mitochondrial metabolism, facilitating combination therapy and noninvasive magnetic resonance spectroscopy. Cancer Res. 2017;77:5913\u201324. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2686.","journal-title":"Cancer Res"},{"key":"776_CR283","doi-asserted-by":"publisher","DOI":"10.1172\/JCI177606","volume":"134","author":"S Verma","year":"2024","unstructured":"Verma S, Budhu S, Serganova I, Dong L, Mangarin LM, Khan JF, et al. Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models. J Clin Invest. 2024;134:e177606. https:\/\/doi.org\/10.1172\/JCI177606.","journal-title":"J Clin Invest"},{"key":"776_CR284","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41586-022-04758-2","volume":"605","author":"M Rossi","year":"2022","unstructured":"Rossi M, Altea-Manzano P, Demicco M, Doglioni G, Bornes L, Fukano M, et al. PHGDH heterogeneity potentiates cancer cell dissemination and metastasis. Nature. 2022;605:747\u201353. https:\/\/doi.org\/10.1038\/s41586-022-04758-2.","journal-title":"Nature"},{"key":"776_CR285","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41423-024-01134-0","volume":"21","author":"Z Cai","year":"2024","unstructured":"Cai Z, Li W, Hager S, Wilson JL, Afjehi-Sadat L, Heiss EH, et al. Targeting PHGDH reverses the immunosuppressive phenotype of tumor-associated macrophages through \u03b1-ketoglutarate and mTORC1 signaling. Cell Mol Immunol. 2024;21:448\u201365. https:\/\/doi.org\/10.1038\/s41423-024-01134-0.","journal-title":"Cell Mol Immunol"},{"key":"776_CR286","doi-asserted-by":"publisher","DOI":"10.1038\/s44324-024-00005-6","volume":"2","author":"N Pardo-Lorente","year":"2024","unstructured":"Pardo-Lorente N, Sdelci S. MTHFD2 in healthy and cancer cells: canonical and non-canonical functions. NPJ Metab Health Dis. 2024;2:3. https:\/\/doi.org\/10.1038\/s44324-024-00005-6.","journal-title":"NPJ Metab Health Dis"},{"key":"776_CR287","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s43018-022-00331-y","volume":"3","author":"N Bonagas","year":"2022","unstructured":"Bonagas N, Gustafsson NMS, Henriksson M, Marttila P, Gustafsson R, Wiita E, et al. Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress. Nat Cancer. 2022;3:156\u201372. https:\/\/doi.org\/10.1038\/s43018-022-00331-y.","journal-title":"Nat Cancer"},{"key":"776_CR288","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","volume":"574","author":"D Zhang","year":"2019","unstructured":"Zhang D, Tang Z, Huang H, Zhou G, Cui C, Weng Y, et al. Metabolic regulation of gene expression by histone lactylation. Nature. 2019;574:575\u201380. https:\/\/doi.org\/10.1038\/s41586-019-1678-1.","journal-title":"Nature"},{"key":"776_CR289","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202413095","volume":"12","author":"J Cai","year":"2025","unstructured":"Cai J, Zhang P, Cai Y, Zhu G, Chen S, Song L, et al. Lactylation-driven NUPR1 promotes immunosuppression of tumor-infiltrating macrophages in hepatocellular carcinoma. Adv Sci (Weinh). 2025;12:e2413095. https:\/\/doi.org\/10.1002\/advs.202413095.","journal-title":"Adv Sci (Weinh)"},{"key":"776_CR290","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1084\/jem.20171068","volume":"215","author":"AV Menk","year":"2018","unstructured":"Menk AV, Scharping NE, Rivadeneira DB, Calderon MJ, Watson MJ, Dunstane D, et al. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J Exp Med. 2018;215:1091\u2013100. https:\/\/doi.org\/10.1084\/jem.20171068.","journal-title":"J Exp Med"},{"key":"776_CR291","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coi.2017.03.011","volume":"46","author":"M Sukumar","year":"2017","unstructured":"Sukumar M, Kishton RJ, Restifo NP. Metabolic reprograming of anti-tumor immunity. Curr Opin Immunol. 2017;46:14\u201322. https:\/\/doi.org\/10.1016\/j.coi.2017.03.011.","journal-title":"Curr Opin Immunol"},{"key":"776_CR292","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-025-01209-8","volume":"33","author":"E Di Carlo","year":"2026","unstructured":"Di Carlo E. Tumor-on-chip\u2019s alliance with molecular pathology against metastatic disease. J Biomed Sci. 2026;33:9. https:\/\/doi.org\/10.1186\/s12929-025-01209-8.","journal-title":"J Biomed Sci"},{"key":"776_CR293","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01419-2","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther. 2023;8:160. https:\/\/doi.org\/10.1038\/s41392-023-01419-2.","journal-title":"Signal Transduct Target Ther"},{"key":"776_CR294","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s42255-025-01338-2","volume":"7","author":"AD Rao","year":"2025","unstructured":"Rao AD, Cai L, Snyman M, Walsdorf RE, Li X, Wix SN, et al. Conservation and divergence of metabolic phenotypes between patient tumours and matched xenografts. Nat Metab. 2025;7:1703\u201313. https:\/\/doi.org\/10.1038\/s42255-025-01338-2.","journal-title":"Nat Metab"},{"key":"776_CR295","doi-asserted-by":"publisher","first-page":"137","DOI":"10.15252\/emmm.201606857","volume":"9","author":"K Kersten","year":"2017","unstructured":"Kersten K, de Visser KE, van Miltenburg MH, Jonkers J. Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med. 2017;9:137\u201353. https:\/\/doi.org\/10.15252\/emmm.201606857.","journal-title":"EMBO Mol Med"}],"container-title":["Experimental Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00776-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00776-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00776-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:02:47Z","timestamp":1790337767000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00776-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":295,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["776"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00776-2","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"98"}}